Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• c-KIT also known as KIT, CD117, and stem cell factor receptor
• KIT is a 145 kDa transmembrane tyrosine kinase protein that acts as a type-Ill receptor
• the c-KIT proto-oncogene located on chromosome 4ql 1-21, encodes the c- KIT receptor, whose ligand is the stem cell factor (SCF, steel factor, kit ligand, mast cell growth factor, Morstyn, G. et al. Oncology 1994, 57(2), pg. 205; Yarden, Y. et al. Embo. J.
• the receptor has tyrosine-protein kinase activity and binding of the ligand SCF leads to the autophosphorylation of c-KIT and its association with substrates such as phosphatidylinositol 3-kinase (PI3K).
• Tyrosine phosphorylation by protein tyrosine kinases is of particular importance in cellular signaling and can mediate signals for major cellular processes, such as proliferation, survival, differentiation, apoptosis, attachment, invasiveness and migration.
• Defects in c-KIT are a cause of piebaldism, an autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.
• Gain-of-function mutations of the c- KIT gene and the expression of constitutively phosphorylated c-KIT are found in most gastrointestinal stromal tumors GIST) and mastocytosis. Further, almost all gonadal seminomas/dysgerminomas exhibit c-KIT membranous staining, and several reports have clarified that some (10-25%) have a c-KIT gene mutation (Sakuma, Y. et al. Cancer Sci. 2004, 95(9), pg. 716). c-KIT defects have also been associated with testicular tumors including germ cell tumors (GCT) and testicular germ cell tumors (TGCT).
• GCT germ cell tumors
• TGCT testicular germ cell tumors
• c-KIT expression has been studied in hematologic and solid tumors, such as acute leukemias (Cortes, J. et al. Cancer 2003, 97(11), pg. 2760) and GIST (Fletcher, J. et al. Hum. Pathol. 2002, 55(5), pg. 459).
• the clinical importance of c-KIT expression in malignant tumors relies on studies with Gleevec ® (imatinib mesylate, STI571 (signal transduction inhibitor number 571), Novartis Pharma AG Basel, Switzerland) that specifically inhibits tyrosine kinase receptors (Lefevre, G. et al. J. Biol. Chem.
• c-KIT exon 11 The majority of primary GIST-causing c-KIT mutations affect the juxtamembrane (JM) region of the protein encoded by exon 11 (i.e. V560D) and consist of in-frame deletions or insertions, or missense mutations.
• JM juxtamembrane
• c-KIT exon 11 mutations have been identified as primary mutations in approximately 75% of GISTs.
• Such JM domain mutations disrupt the autoinhibition mechanism of c-KIT kinase, leading to constitutive kinase activity and cell- transforming events causative of GIST (Chen, L.L. et al. Clin. Cancer Res. 2005, 11, pg. 3668-3677; Mol, CD., et al. J. Biol. Chem. 2004, 279, pg. 31655-31663).
• GIST most often become Gleevec® resistant, and molecularly targeted small molecule therapies that target c-KIT secondary mutations remain elusive.
• GIST patients who relapse after treatment with Gleevec® or Sutent® have disease still driven by c-KIT mutations. These secondary mutations occur on the same alleles as the primary JM-region mutation, and thus represent even more aggressive activated forms of c-KIT than the original primary mutation.
• These secondary mutants of c-KIT identified in GIST lead to acquired drug resistance. Secondary mutations are found in the extracellular domain of c-KIT (exon 9, i.e. AY501-502 duplication/insertion), ATP binding pocket (exon 13, i.e.
• Sunitinib malate (SutentTM, Pfizer) is an inhibitor of multiple RTKs, notably in this context, c-KIT and PDGFRa, and has been shown to be effective against certain imatinib-resistant c-KIT mutants, such as the ATP-binding pocket mutants V654A and T670I.
• Certain Gleevec ® -resistant mutants are also resistant to sunitinib, such as D816H and D816V which are located in the activation loop of the c-KIT catalytic domain encoded by exon 17 (Corless et al. J. Clin. Oncol. 2004, 22, pg. 3813; Heinrich et al. J. Clin. Oncol.
• the present invention discloses the unexpected utility of compounds that inhibit c- KIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.
• D816 mutations in c-KIT have been demonstrated to cause mastocytosis, mast cell leukemia, seminomas, dysgerminomas, lymphomas, and intracranial teratomas (Ning, A.Q, Li, J., and Arceci, R.J. Leuk Lymphoma, 2001, 41, pg. 513-522; Beghini, A., et al. Blood, 2000, 95, pg. 726-727; Tian, Q., et al. Am J. Pathol. 1999, 154, pg. 1643-1647; Nagata, H., et al. Proc. Natl. Acad. Sci.
• the present invention also discloses new compounds for the treatment of diseases caused by c-KIT mutation, including new compounds for the treatment of refractory GIST, mast cell leukemia, or mastocytosis.
• One aspect of the present invention provides a method of treating a disease caused by the kinase activity of c-KIT, oncogenic forms thereof, aberrant fusion proteins thereof or polymorphs thereof, comprising the administration of a compound of formula la or a pharmaceutically acceptable salt thereof,
• A is selected from the group consisting of phenyl, naphthyl, and benzothienyl;
• Gl is a heteroaryl taken from the group consisting of pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, triazinyl, pyridinyl, and pyrimidinyl;
• G4 is a heterocyclyl taken from the group consisting of oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, imidazolonyl, pyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, and morpholinyl; when A has one or more substitutable sp2-hybridized carbon atom, each respective sp2 hybridized carbon atom may be optionally substituted with a Z3 substituent;
• Zl is selected from the group consisting of -NH(R4), and -NHCOR8; in the event that Zl contains an alkyl or alkylene moiety, such moieties may be further substituted with one or more Cl-C6alkyls; each Z2 is independently and individually selected from the group consisting of hydrogen, Cl-C6alkyl, C3-C8carbocyclyl, C1-C6 alkoxy, hydroxyl, hydroxyCl-C6alkyl-, cyano, (R3) 2 N-, and -(CH 2 ) n R5; in the event that Z2 contains an alkyl or alkylene moiety, such moieties may be further substituted with one or more Cl-C6alkyls; each Z3 is independently and individually selected from the group consisting of H, methyl, ethyl, isopropyl, C3-C4 carbocyclyl, halogen, cyano, -(CH 2 ) k -N(R
• the invention provides a method of treating a disease caused by the kinase activity of c-KIT, oncogenic forms thereof, aberrant fusion proteins thereof or polymorphs thereof, wherein c-KIT contains a missense mutatation, insertion mutation, or a deletion mutation encoded by exons comprising Exon 9, Exon 11, Exon 13, Exon 14, Exon 17, or Exon 18, presenting either individually or in combination, comprising the administration of a compound of formula la or a pharmaceutically acceptable salt thereof.
• a second aspect of the present invention provides a method of treating a disease selected from gastrointestinal stromal tumors, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, melanoma, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, colonic cancers, acute myeloid leukemia, germ cell tumors of the seminoma or dysgerminoma, teratomas, mastocytosis, or mast cell leukemia, said method comprising administering a therapeutically effective amount of a compound of Formula la, or a pharmaceutically acceptable salt thereof, to a patient.
• a third aspect of the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of Formula la, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier, with the proviso that the compound is not l-(5-(l-ethyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2-fluoro-4- methylphenyl)-3-(naphthalen- 1 -yl)urea, 1 -(5-(l -ethyl-7-(methylamino)-2-oxo- 1 ,2- dihydro- 1 ,6-naphthyridin-3 -yl)-2-fluorophenyl)-3 -(naphthalen- 1 -yl)urea, 1 -(4-chloro-5 -( 1 - ethyl-7-(methylamino)-2-oxo
• a fourth aspect of the present invention provides use of a compound of Formula la or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease selected from gastrointestinal stromal tumors, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, melanoma, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, colonic cancers, acute myeloid leukemia, germ cell tumors of the seminoma or dysgerminoma, teratomas, mastocytosis, or mast cell leukemia.
• a disease selected from gastrointestinal stromal tumors, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, melanoma, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, papillary thyroid carcinoma, non-
• a fifth aspect of the present invention provides a compound of formula la
• A is selected from the group consisting of phenyl, naphthyl, and benzothienyl;
• Gl is a heteroaryl taken from the group consisting of pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, triazinyl, pyridinyl, and pyrimidinyl;
• G4 is a heterocyclyl taken from the group consisting of oxetanyl, azetadinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, imidazolonyl, pyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, and morpholinyl; when A has one or more substitutable sp2-hybridized carbon atom, each respective sp2 hybridized carbon atom may be optionally substituted with a Z3 substituent;
• Zl is selected from the group consisting of -NH(R4), and -NHCOR8; in the event that Zl contains an alkyl or alkylene moiety, such moieties may be further substituted with one or more Cl-C6alkyls; each Z2 is independently and individually selected from the group consisting of hydrogen, Cl-C6alkyl, C3-C8carbocyclyl, C1-C6 alkoxy, hydroxyl, hydroxyCl-C6alkyl-, cyano, (R3) 2 N-, and -(CH 2 ) n R5; in the event that Z2 contains an alkyl or alkylene moiety, such moieties may be further substituted with one or more Cl-C6alkyls; each Z3 is independently and individually selected from the group consisting of H, methyl, ethyl, isopropyl, C3-C4 carbocyclyl, halogen, cyano, -(CH 2 ) k -N(R
• Rl is selected from the group consisting of Cl-C4alkyl, branched C3-C5alkyl, and C3- C5 carbocyclyl; each R2 is independently and individually selected from the group consisting of hydrogen, methyl, ethyl, halogen, fluoroalkyl wherein the alkyl moiety can be partially or fully fluorinated, cyano, and C2-C3alkynyl; each R3 is independently and individually selected from the group consisting of H, Cl- C6alkyl, branched C3-C7alkyl, and C3-C8carbocyclyl; each R4 is independently and individually selected from the group consisting of H, Cl- C6alkyl, hydroxyC2-C6alkyl, Cl-C6alkoxyC2-C6alkyl, branched C3-C7alkyl, branched hydroxyC2-C6alkyl, branched Cl-C6alkoxyC2-C6alkyl, -(
• the compound of Formula la is a compound wherein: A is phenyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: A is naphthyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: A is benzothienyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Rl is taken from the group consisting of Cl-C4alkyl, branched C3-C5alkyl, and C3-C5carbocyclyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Rl is Cl- C4alkyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Rl is branched C3-C5alkyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Rl is C3- C5carbocyclyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is selected from the group consisting of -NH(R4) and -NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NH(R4); or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NH(R4) and R4 is H or Cl-C6alkyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NH(R4) and R4 is H; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NH(R4) and R4 is Cl-C6alkyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NR4COR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NHCOR8 and R8 is hydrogen, Cl-C6alkyl, branched C3-C7alkyl, C3-C8carbocyclyl, - N(R4)2, or R5; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NHCOR8 and R8 is Cl-C6alkyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NHCOR8 and R8 is branched C3-C7alkyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NHCOR8 and R8 is C3-C8carbocyclyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NHCOR8 and R8 is -N(R4)2; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: Zl is - NHCOR8 and R8 is R5; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound wherein: each R2 is independently hydrogen, methyl, or halogen and t is 2; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb
• R2 is hydrogen, methyl, or halogen; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: R2 is hydrogen; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: R2 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: R2 is halogen; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is phenyl, Rl is Cl-C4alkyl, branched C3-C5alkyl, or C3-C5carbocyclyl, R2 is hydrogen, methyl, or halogen, and Zl is -NH(R4) or -NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is phenyl, Rl is Cl-C4alkyl, R2 is methyl or halogen, and Zl is -NH(R4) or - NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is phenyl, Rl is ethyl, R2 is methyl or halogen, and Zl is -NH(R4) or -NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is phenyl, Rl is ethyl, R2 is methyl or halogen, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is phenyl, Rl is ethyl, R2 is methyl, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is phenyl, Rl is ethyl, R2 is halogen, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is naphthyl, Rl is Cl-C4alkyl, branched C3-C5alkyl, or C3-C5carbocyclyl, R2 is hydrogen, methyl, or halogen, and Zl is -NH(R4) or -NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is naphthyl, Rl is Cl-C4alkyl, R2 is methyl or halogen, and Zl is -NH(R4) or - NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is naphthyl, Rl is ethyl, R2 is methyl or halogen, and Zl is -NH(R4) or - NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is naphthyl, Rl is ethyl, R2 is methyl or halogen, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is naphthyl, Rl is ethyl, R2 is methyl, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is naphthyl, Rl is ethyl, R2 is halogen, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is benzothienyl, Rl is Cl-C4alkyl, branched C3-C5alkyl, or C3-C5carbocyclyl, R2 is hydrogen, methyl, or halogen, and Zl is -NH(R4) or -NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is benzothienyl, Rl is Cl-C4alkyl, R2 is methyl or halogen, and Zl is -NH(R4) or -NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is benzothienyl, Rl is ethyl, R2 is methyl or halogen, and Zl is -NH(R4) or - NHCOR8; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is benzothienyl, Rl is ethyl, R2 is methyl or halogen, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is benzothienyl, Rl is ethyl, R2 is methyl, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the compound of Formula la is a compound of Formula lb wherein: A is benzothienyl, Rl is ethyl, R2 is halogen, Zl is -NH(R4) and R4 is methyl; or a pharmaceutically acceptable salt thereof.
• the present invention provides a method treating a disease caused by c-KIT kinase comprising gastrointestinal stromal tumors, ovarian cancer, melanoma, cervical carcinomas, acute myeloid leukemia, germ cell tumors of the seminoma or dysgerminoma, teratomas, mastocytosis, or mast cell leukemia, said method comprising administering to a patient a therapeutically effective amount of a compound selected from 1- (5-(l-ethyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2-fluoro-4- methylphenyl)-3-(naphthalen- 1 -yl)urea, 1 -(5-(l -ethyl-7-(methylamino)-2-oxo- 1 ,2- dihydro- 1 ,6-naphthyridin-3 -y
• the present invention comprises a compound selected from the group consisting of l-(4-chloro-3-(l-methyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6- naphthyridin-3 -yl)phenyl)-3 -(3 -cyanophenyl)urea, 1 -(3 -cyanophenyl)-3 -(5 -( 1 -ethyl-7- (methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2-fluorophenyl)urea, 1- (benzo[b]thiophen-3-yl)-3-(2-fluoro-4-methyl-5-(l-methyl-7-(methylamino)-2-oxo-l,2- dihydro-l,6-naphthyridin-3-yl)phenyl)urea, l-(
• fluorophenyl)urea 1 -(5-( 1 -ethyl-7-(2-methoxyethylamino)-2-oxo- 1 ,2-dihydro- 1 ,6- naphthyridin-3-yl)-2,4-difluorophenyl)-3-phenylurea, l-(5-(l-ethyl-7-(2- methoxyethylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)-2-fluoro-4-methylphenyl)-3 - phenylurea, l-(5-(l-ethyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2- fluoro-4-methylphenyl)-3-(2-fluorophenyl)urea, l-(
• phenylurea 1 -(4-chloro-5-( 1 -ethyl-7-(methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin- 3-yl)-2-fluorophenyl)-3-(3,5-difluorophenyl)urea, l-(4-bromo-2-fluoro-5-(l-methyl-7- (methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)phenyl)-3 -phenylurea, 1 -(5 -(7- amino- 1 -ethyl-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)-4-bromo-2-fluorophenyl)-3 - phenylurea, 1 -(5-(7-
• the compounds of this disclosure include any and all possible isomers, stereoisomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and solvates thereof, as well as crystalline polymorphic forms of the disclosed compounds and any and all possible isomers, stereoisomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and solvates thereof.
• the terms "compound,” “compounds,” “test compound,” or “test compounds” as used in this disclosure refer to the compounds of this disclosure and any and all possible isomers, stereoisomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, solvates, and crystalline polymorphs thereof.
• alkyl refers to straight chain alkyl, wherein alkyl chain length is indicated by a range of numbers, in exemplary embodiments, "alkyl” refers to an alkyl chain as defined above containing 1, 2, 3, 4, 5, or 6 carbons (i.e., C1-C6 alkyl). Examples of an alkyl include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, and hexyl.
• branched alkyl refers to an alkyl chain wherein a branching point in the chain exists, and the total number of carbons in the chain is indicated by a range of numbers.
• branched alkyl refers to an alkyl chain as defined above containing 3, 4, 5, 6, or 7 carbons (i.e., C3-C7 branched alkyl).
• Examples of branched alkyl include, but are not limited to, z ' so-propyl, z ' so-butyl, secondary-butyl, tertiary-butyl, 2- pentyl, 3-pentyl, 2-hexyl, and 3-hexyl.
• alkoxy refers to -O-(alkyl), wherein “alkyl” is as defined above.
• branched alkoxy refers to -0-(branched alkyl), wherein “branched alkyl” is as defined above.
• alkylene refers to an alkyl moiety interposed between two other atoms.
• alkylene refers to an alkyl moiety as defined above containing 1, 2, or 3 carbons.
• alkylene groups include, but are not limited to -CH 2 -, -CH 2 CH 2 -, and -CH 2 CH 2 CH 2 -.
• alkylene groups are branched.
• alkynyl refers to a carbon chain containing one carbon- carbon triple bond.
• alkynyl refers to a carbon chain as described above containing 2 or 3 carbons (i.e., C2-C3 alkynyl).
• alkynyl group examples include, but are not limited to, ethyne and propyne.
• aryl refers to a cyclic hydrocarbon, where the ring is characterized by delocalized ⁇ electrons (aromaticity) shared among the ring members, and wherein the number of ring atoms is indicated by a range of numbers.
• aryl refers to a cyclic hydrocarbon as described above containing 6, 7, 8, 9, or 10 ring atoms (i.e., C6-C10 aryl). Examples of an aryl group include, but are not limited to, benzene, naphthalene, tetralin, indene, and indane.
• cycloalkyl refers to a monocyclic saturated carbon ring, wherein the number of ring atoms is indicated by a range of numbers.
• cycloalkyl refers to a carbon ring as defined above containing 3, 4, 5, 6, 7, or 8 ring atoms (i.e., C3-C8 cycloalkyl).
• Examples of a cycloalkyl group include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
• halogen or "halo” as used herein refers to fluorine, chlorine, bromine, and iodine.
• heterocycle or “heterocyclyl” as used herein refers to a cyclic hydrocarbon, wherein at least one of the ring atoms is an O, N, or S, wherein the number of ring atoms is indicated by a range of numbers. Heterocyclyl moieties as defined herein have C or N bonding hands. For example, in some embodiments, a ring N atom from the heterocyclyl is the bonding atom of the heterocylic moiety.
• heterocyclyl refers to a cyclic hydrocarbon as described above containing 4, 5, or 6 ring atoms (i.e., C4-C6 heterocyclyl).
• heterocycle group examples include, but are not limited to, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, pyran, thiopyran, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S-dioxide, oxazoline, tetrahydrothiophene, piperidine, tetrahydropyran, thiane, imidazolidine, oxazolidine, thiazolidine, dioxolane, dithiolane, piperazine, oxazine, dithiane, and dioxane.
• heteroaryl refers to a cyclic hydrocarbon, where at least one of the ring atoms is an O, N, or S, the ring is characterized by delocalized ⁇ electrons (aromaticity) shared among the ring members, and wherein the number of ring atoms is indicated by a range of numbers.
• Heteroaryl moieties as defined herein have C or N bonding hands.
• a ring N atom from the heteroaryl is the bonding atom of the heteroaryl moiety.
• heteroaryl refers to a cyclic hydrocarbon as described above containing 5 or 6 ring atoms (i.e., C5-C6 heteroaryl).
• heteroaryl group include, but are not limited to, pyrrole, furan, thiene, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine, pyridazine, and triazine.
• substituted in connection with a moiety as used herein refers to a further substituent which is attached to the moiety at any acceptable location on the moiety. Unless otherwise indicated, moieties can bond through a carbon, nitrogen, oxygen, sulfur, or any other acceptable atom.
• salts as used herein embraces pharmaceutically acceptable salts commonly used to form alkali metal salts of free acids and to form addition salts of free bases.
• the nature of the salt is not critical, provided that it is pharmaceutically acceptable.
• Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid.
• Exemplary pharmaceutical salts are disclosed in Stahl, P.H., Wermuth, C.G., Eds. Handbook of Pharmaceutical Salts: Properties, Selection and Use; Verlag Helvetica Chimica Acta/Wiley-VCH: Zurich, 2002, the contents of which are hereby incorporated by reference in their entirety.
• inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
• Appropriate organic acids include, without limitation, aliphatic, cycloaliphatic, aromatic, arylaliphatic, and heterocyclyl containing carboxylic acids and sulfonic acids, for example formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, /?-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanethane
• Suitable pharmaceutically acceptable salts of free acid-containing compounds disclosed herein include, without limitation, metallic salts and organic salts.
• Exemplary metallic salts include, but are not limited to, appropriate alkali metal (group la) salts, alkaline earth metal (group Ila) salts, and other physiological acceptable metals.
• Such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.
• Exemplary organic salts can be made from primary amines, secondary amines, tertiary amines and quaternary ammonium salts, for example, tromethamine, diethylamine, tetra-N-methylammonium, ⁇ , ⁇ '- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
• administer refers to either directly administering a compound or pharmaceutically acceptable salt of the compound or a composition to a subject.
• carrier encompasses carriers, excipients, and diluents, meaning a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ or portion of the body.
• disorder is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
• the terms "effective amount” and “therapeutically effective amount” are used interchangeably in this disclosure and refer to an amount of a compound that, when administered to a subject, is capable of reducing a symptom of a disorder in a subject.
• the actual amount which comprises the "effective amount” or “therapeutically effective amount” will vary depending on a number of conditions including, but not limited to, the particular disorder being treated, the severity of the disorder, the size and health of the patient, and the route of administration. A skilled medical practitioner can readily determine the appropriate amount using methods known in the medical arts.
• the terms "isolated” and “purified” as used herein refer to a component separated from other components of a reaction mixture or a natural source.
• the isolate contains at least about 50%, at least about 55%, at least about 60%, at least about 65%o, at least about 70%>, at least about 75%, at least about 80%>, at least about 85%, at least about 90%, at least about 95%, or at least about 98% of the compound or pharmaceutically acceptable salt of the compound by weight of the isolate.
• phrases "pharmaceutically acceptable” as used herein refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• the terms "patient” or “subject” include, without limitation, a human or an animal.
• exemplary animals include, but are not limited to, mammals such as mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon, or rhesus monkey.
• “Therapeutically effective amount” or “effective amount” means the dosage of the compound, or pharmaceutically acceptable salt thereof, or pharmaceutical composition containing an exemplified compound of Formula I, or pharmaceutically acceptable salt thereof, necessary to inhibit c-KIT signaling in a cancer patient, and either destroy the target cancer cells or slow or arrest the progression of the cancer in a patient.
• the exact dosage required to treat a patient and the length of treatment time will be determined by a physician in view of the stage and severity of the disease as well as the specific needs and response of the individual patient and the particular compound administered. Although expressed as dosage on a per day basis, the dosing regimen may be adjusted to provide a more optimal therapeutic benefit to a patient. In addition to daily dosing, twice-a-day (BID) or thrice-a-day (TID) dosing may be appropriate. BID dosing is currently preferred.
• treatment are meant to include the full spectrum of intervention for the cancer from which the patient is suffering, such as administration of the active compound to alleviate, slow or reverse one or more of the symptoms and to delay progression of the cancer even if the cancer is not actually eliminated. Treating can be curing, improving, or at least partially ameliorating the disorder.
• the patient to be treated is a mammal, in particular a human being.
• hydrate refers to a compound disclosed herein which is associated with water in the molecular form, i.e., in which the H— OH bond is not split, and may be represented, for example, by the formula R H 2 0, where R is a compound disclosed herein.
• R is a compound disclosed herein.
• a given compound may form more than one hydrate including, for example, monohydrates (R H 2 0), dihydrates (R 2H 2 0), trihydrates (R 3H 2 0), and the like.
• solvate refers to a compound disclosed herein which is associated with solvent in the molecular form, i.e., in which the solvent is coordinatively bound, and may be represented, for example, by the formula R'(solvent), where R is a compound disclosed herein.
• a given compound may form more than one solvate including, for example, monosolvates (R'(solvent)) or polysolvates (R'n(solvent)) wherein n is an integer greater than 1) including, for example, disolvates (R'2(solvent)), trisolvates (R'3(solvent)), and the like, or hemisolvates, such as, for example, R-n/2(solvent), R'n/3(solvent), R-n/4(solvent) and the like, wherein n is an integer.
• Solvents herein include mixed solvents, for example, methanol/water, and as such, the solvates may incorporate one or more solvents within the solvate.
• the term "acid hydrate” as used herein refers to a complex that may be formed through association of a compound having one or more base moieties with at least one compound having one or more acid moieties or through association of a compound having one or more acid moieties with at least one compound having one or more base moieties, said complex being further associated with water molecules so as to form a hydrate, wherein said hydrate is as previously defined and R represents the complex herein described above.
• Structural, chemical and stereochemical definitions are broadly taken from IUPAC recommendations, and more specifically from Glossary of Terms used in Physical Organic Chemistry (IUPAC Recommendations 1994) as summarized by Miiller, P. Pure Appl. Chem. 1994, 66, pp. 1077-1184 and Basic Terminology of Stereochemistry (IUPAC Recommendations 1996) as summarized by Moss, G.P. Pure Appl. Chem. 1996, 68, pp. 2193-2222.
• Atropisomers are defined as a subclass of conformers which can be isolated as separate chemical species and which arise from restricted rotation about a single bond.
• Enantiomers are defined as one of a pair of molecular entities which are mirror images of each other and non-superimposable.
• Diastereomers or diastereoisomers are defined as stereoisomers other than enantiomers. Diastereomers or diastereoisomers are stereoisomers not related as mirror images. Diastereoisomers are characterized by differences in physical properties, and by some differences in chemical behavior towards achiral as well as chiral reagents.
• tautomer refers to compounds produced by the phenomenon wherein a proton of one atom of a molecule shifts to another atom. See March, Advanced Organic Chemistry: Reactions, Mechanisms and Structures, 4th Ed., John Wiley & Sons, pp. 69-74 (1992). Tautomerism is defined as isomerism of the general form
• Tautomers are readily interconvertible; the atoms connecting the groups X, Y and Z are typically any of C, H, O, or S, and G is a group which becomes an electro fuge or nucleofuge during isomerization.
• electrofuge H +
• prototropy The most common case, when the electrofuge is H + , is also known as "prototropy.”
• Tautomers are defined as isomers that arise from tautomerism, independent of whether the isomers are isolable.
• the exemplified compounds of the present invention are preferably formulated as a pharmaceutical composition using a pharmaceutically acceptable carrier and administered by a variety of routes.
• a pharmaceutically acceptable carrier Preferably, such compositions are for oral administration.
• Such pharmaceutical compositions and processes for preparing them are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al, eds., 19 th ed., Mack Publishing Co., 1995).
• the pharmaceutical composition comprises l-(3,3-dimethylbutyl)-3- ⁇ 2-fluoro-4-methyl-5-[7- methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl ⁇ urea, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients particularly for treatment of cancer generally or a specific cancer type.
• the exemplified compounds of the present invention are capable of reaction with a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
• Such pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al, HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); S.M. Berge, et al, "Pharmaceutical Salts, " Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977.
• the compounds of Formula la, or a pharmaceutically acceptable salt thereof may be prepared by a variety of procedures known in the art, as well as those described below. The specific synthetic steps may be combined in different ways to prepare the Formula la compounds, or a pharmaceutically acceptable salt thereof.
• ChemDraw version 10 or 12 was used to name the structures of intermediates and exemplified compounds.
• ADP is adenosine diphosphate
• AIBN is azobisisobutyronitrile
• ATP is adenosine triphosphate
• BippyPhos is 5-(di-tert-butylphosphino)- ,3',5'-triphenyl- H- [l,4']bipyrazole
• BrettPhos Palladacycle is chloro[2-(dicyclohexylphosphino)-3,6- dimethoxy-2'-4'-6'-tri-i-propyl- 1 , 1 '-biphenyl] [2-(2-aminoethyl)phenyl]palladium(II), "cone.” is concentrated
• DBU is l,8-diazabicyclo[5.4.0]undec-7-ene
• DCM is dichloromethane
• the compounds of Formula la (1) are prepared by the general synthetic methods illustrated in the schemes below and the accompanying examples. Suitable reaction conditions for the steps of these schemes are well known in the art and appropriate substitutions of solvents and co-reagents are within the skill of the art. Those skilled in the art will understand that synthetic intermediates may be isolated and/or purified by well known techniques as needed or desired, and that it will be possible to use various intermediates directly in subsequent synthetic steps with little or no purification. Furthermore, those skilled in the art will appreciate that in some instances, the order in which moieties are introduced is not critical.
• the compounds of Formula la (1) frequently contain -NH moieties in the Zl position. It will be understood by those skilled in the art that in some instances it may be advantageous to use an amine protecting group during synthesis to temporarily mask one or more -NH moieties. Said protecting group can be removed from any subsequent intermediate leading to the synthesis of compound 1, using standard conditions that effect removal of said protecting group, said conditions of which will be familiar to those skilled in the art. When not specified in a scheme, it will be understood by those skilled in the art that the Zl moiety represented in the schemes below may optionally contain a standard NH- protecting group that can be removed at any opportune time in the synthetic sequence.
• intermediates wherein Zl is aminomethyl may be obtained directly by the introduction of methylamine into a synthetic scheme, or alternately by introduction of a "protected" form of methylamine, for example l-(4-methoxyphenyl)-N-methylmethanamine to provide intermediates wherein Zl is l-(4-methoxyphenyl)-N-methylmethanamino.
• a "protected" form of methylamine for example l-(4-methoxyphenyl)-N-methylmethanamine to provide intermediates wherein Zl is l-(4-methoxyphenyl)-N-methylmethanamino.
• Scheme 1 illustrates general preparations of compounds of formula 1 from 7-chloro- naphthyridinone 2.
• Conversion of chloride 2 to Zl -substituted intermediate 3 can be accomplished by numerous methods familiar to those skilled in art, the choice of which is dictated by the specific nature of Zl .
• Further conversion of intermediate 3 to ureas of formula 1 is accomplished by one of three methods.
• reaction of 3 with isocyanates of formula 4 provides ureas of formula 1.
• Many isocyanates (4) are commercially available and those that are not can be readily prepared from the corresponding amines (9) by reaction of said amines with phosgene or an equivalent such as triphosgene or carbonyl diimidazole.
• Conditions to effect the transformation of 3 to 1 include treating 3 with 4 in an aprotic solvent such as DCM, THF or EtOAc, optionally in the presence of a base, for example pyridine, and optionally while heating said mixtures.
• an aprotic solvent such as DCM, THF or EtOAc
• a base for example pyridine
• reaction of 3 with carbamates of formula 5 also affords ureas of formula J_.
• Conditions to effect the transformation of 3 to 1 include treating 3 with 5 in an aprotic solvent such as 1,4-dioxane, THF or DMSO, in the presence of a base, for example N- methylpyrrolidine, diisopropylethylamme, or triethylamine, and heating the resulting mixture.
• Suitable carbamates (5) include isopropenyl, 2,2,2, -trichloroethyl and phenyl (or substituted phenyl) carbamates. These carbamates 5 can be readily prepared by reaction with amines 9 with the appropriate chloroformate as familiar to those skilled in the art. In a third embodiment, carboxylic acids of formula 5 can be subjected to a Curtius rearrangement in the presence of amine 3 to provide ureas of formula 1.
• Conditions to effect said transformation include combining amine 3, carboxylic acid 5 and diphenylphosphoryl azide (DPP A), and a base, for example triethylamine, and heating said mixture in an aprotic solvent, such as 1 ,4- dioxane, in a temperature range of 50-120 °C to effect the rearrangement.
• DPP A diphenylphosphoryl azide
• a base for example triethylamine
• compound 3 can also be converted to 1 via two-step process by first converting 3 to carbamate 8, followed by reaction of carbamate 8 with amine 9.
• suitable carbamates (8) include isopropenyl, 2,2,2, -trichloroethyl and phenyl (or substituted phenyl) carbamates.
• a base for example N- methylpyrrolidine, diisopropylethylamme, or triethylamine
• 7-chloro-naphthyridinone 2 can also be converted to urea 7 or carbamate 10, respectively. Further conversion of urea 7 to urea 1 is then accomplished by reaction of 7 with a generic Zl amine, amide, urea or carbamic acid in the presence of a Palladium catalyst (Buchwald-type coupling), as further illustrated below.
• Scheme 2
• Scheme 2 illustrates the preparation of compounds of formula 1_5, compounds of formula wherein Zl is -NHR4.
• Conditions for the conversion of 2 to 1_3 or f4 include heating an amine of formula 12a or 12b with chloride 2, optionally in the presence of an additional base, for example DBU (1 ,8- diazabicyclo[5.4.0]undec-7-ene), and optionally in the presence of microwave irradiation.
• ureas 15 or 16 can also be prepared from chloride 7 (scheme 1) by reaction with amine 12a or 12b in the presence of a suitable palladium catalyst, for example the catalyst prepared from Pd(OAc) 2 or Pd 2 (dba) 3 [tris(dibenzylideneacetone)dipalladium] and a ligand such as Xantphos [4,5- bis(diphenylphosphino)-9,9-dimethylxanthene] or BippyPhos [5-(di-tert-butylphosphino)- ,3',5'-triphenyl- H-[l ,4']bipyrazole] in the presence of a base, for example K 2 C0 3 .
• a suitable palladium catalyst for example the catalyst prepared from Pd(OAc) 2 or Pd 2 (dba) 3 [tris(dibenzylideneacetone)dipalladium] and a ligand such as Xantpho
• Scheme 3 illustrates the preparation of 21_, a compound of formula 1 wherein Zl is - N(R4)COR8.
• treatment of chlorides 2 or 7 with generic carbonylamine 19 in the presence of a suitable palladium catalyst provides amides, ureas, or carbamates (according to the R8 moiety) of formula 20 or 21_ respectively.
• Further conversion of 20 to 2J_ is accomplished, as described above, by treatment of 20 with 4, 5, or 6. Alternately, 20 can first be converted to carbamate 22. As described above, further treatment of 22 with amine 9 provides urea 21.
• Scheme 4 illustrates alternate preparations of 21_, 27 and 28 starting from intermediate 15 (scheme 2).
• the X-moiety of 23 represents a generalized leaving group.
• R8 is -NHR4
• isocyanates of formula R4-NCO can be substituted for 23.
• the resulting ureas 27 and 28 can be prepared by reaction of a suitable carbamate 24 with amine 25 or heterocyclic amine 26, respectively.
• suitable carbamates include alkyl, isopropenyl, 2,2,2,- trichloroethyl and phenyl (or substituted phenyl) carbamates.
• Scheme 5 illustrates the general preparation of 7-chloro-naphthyridinones 2.
• Treatment of ethyl 4,6-dichloronicotinate (29, see: Example C3) with R1-NH 2 30 provides the 4-aminopyridine 3J..
• Conditions for this transformation include polar solvents such as DMF, THF, acetonitrile, dioxane, water or mixtures thereof in the presence of optionally added bases such as triethylamine at temperatures between 0 °C and 100 °C.
• Reduction of 31_ for example by treatment with lithium aluminum hydride in THF at temperatures ranging from 0 °C to room temp, provides alcohol 32.
• Oxidation of 32 with manganese dioxide provides aldehyde 33.
• Condensation of 33 with phenylacetate 34 provides general intermediate 2.
• Conditions for this transformation include combining 33 and 34 in DMF or DMAc in the presence of potassium carbonate or cesium carbonate with optional heating (30-150°C) for a period of time ranging from 1 h to 4 days.
• Alternate conditions include combining 33, 34 and alumina-supported potassium fluoride in DMAc with stirring and/or optional sonication and/or optional heating (30-150°C) for a period of 10 min to 48 h.
• Scheme 6 illustrates a general preparation of ester 34.
• Nitration of R2-substituted phenylacetic acid 35 for example by treatment with nitric acid and sulfuric acid provides 36.
• Acid 36 in turn is converted to ethyl ester 37, for example by heating in EtOH in the presence of an acid, such as sulfuric acid.
• reduction of the nitro group provides 34.
• Suitable conditions for this transformation include both hydrogenation over a palladium or nickel catalyst, or reduction with iron or zinc powder in the presence of a proton source, for example ethanolic HC1, acetic acid, or ammonium formate.
• a proton source for example ethanolic HC1, acetic acid, or ammonium formate.
• Alcohol 38 can be obtained from the reduction of a suitably substituted benzoic acid or aldehyde, a sample preparation of which is disclosed below (Example A45).
• Example Al Example A6 (1.61 g, 4.85 mmol), 4-methoxy-N-methylbenzylamine (1.10 g, 7.28 mmol) and DBU (1.09 mL, 7.28 mmol) were combined in NMP (20 mL) and heated at 180°C under Ar overnight. The mixture was cooled to RT, poured into H 2 0 (200 mL) and the resulting solids were collected by filtration and rinsed well with H 2 0.
• Example A2 Using a procedure analogous to Example A8, Example Al (2.06 g, 4.61 mmol) was converted to 3-(5-amino-4-fluoro-2-methylphenyl)-l-ethyl-7- (methylamino)-l,6-naphthyridin-2(lH)-one (1.16 g, 73% yield for 2 steps).
• Example A3 A suspension mixture of Example Bl (3.5 g, 0.019 mol), Example C2 (4.4 g, 0.019 mol) and KF/A1 2 0 3 (10 g) in DMA was stirred at RT for 10 min, poured into water, and extracted with EtOAc (3x). The combined organic phases were washed with brine, dried (Na 2 S0 4 ), concentrated in vacuo and purified by silica gel chromatography to give 3-(5-amino-2-chloro-4-fluorophenyl)-7-chloro-l-ethyl-l,6-naphthyridin-2(lH)-one (4 g, 60% yield).
• Example A4 A mixture of Example A3 (3 g, 8.5mmol) and l-(4-methoxyphenyl)- N-methylmethanamine (20 mL) was charged in a sealed vessel, and then the mixture was heated at 200°C overnight. Volatiles were removed and the residue was purified by column chromatography to give 7-((4-methoxybenzyl)(methyl)amino)-3-(5-amino-2-chloro-4- fluorophenyl)-l -ethyl- l,6-naphthyridin-2(lH)-one (3 g, 73% yield).
• Example A5 To a solution of Example A4 (3 g, 6.2 mmol) in DCM (100 mL) was added TFA (20 mL) at RT, and the resulting mixture was stirred at RT for 6 h. The mixture was extracted with water (2x) and the combined aqueous layers were neutralized with ⁇ 3 ⁇ 2 ⁇ . The resulting precipitate was collected by filtration and dried to give 3-(5-amino- 2-chloro-4-fluorophenyl)-l-ethyl-7-(methylamino)-l,6-naphthyridin-2(lH)-one (1 g, 44% yield).
• Example A6 Example CI (1.32 g, 6.25 mmol, 1.00 eq), Example Bl (1.15 g, 6.25 mmol, 1.00 eq) and KF/A1 2 0 3 (40.00 wt%, 9.08 g, 62.5 mmol, 10.00 eq) were combined in DMA (35 mL) and sonicated for 2 h. The solids were removed via filtration through diatomaceous earth and washed with EtOAc. The combined filtrates were washed with H 2 0 (3x) and the combined aqueous layers were back-extracted with EtOAc (lx).
• Example A7 A solution of Example A18 (22 g, 65.7 mmol), (4-methoxy-benzyl)- methyl-amine (14.9 g, 98.5 mmol) and DBU (15 g, 98.5 mmol) in NMP (120 mL) was heated at 160°C for 5 h.
• Example A8 TFA (3.64 g, 32.0 mmol) was added to Example A7 (0.48 g, 1.06 mmol) and the mixture was stirred for 90 min at RT. Water (50 mL) was added and the reaction mixture was carefully treated with solid Na 2 C0 3 until it was weakly basic. The product was extracted with EtOAc (3x), the combined organics were washed with water (lx), then brine and dried (Na 2 S0 4 ) to afford crude product which was stirred with DCM (2 mL) for 2 h.
• Example A9 A solution of Example A3 (1.90 g, 5.39 mmol), 4- methoxybenzylamine (1.110 g, 8.09 mmol) and DBU (1.232 g, 8.09 mmol) in NMP (15 mL) was heated at 150°C overnight. After cooling to RT, the mixture was diluted with EtOAc (100 mL) and water (100 mL).
• Example A10 Example B2 (0.701 g, 3.53 mmol), Example C2 (0.817 g, 3.53 mmol), and 40% KF on alumina (3.59g, 24.7 mmol) were combined in DMA (5 mL) and the mixture was sonicated for 2 h. The mixture was diluted with EtOAc (10 mL), the solids removed via filtration through diatomaceous earth and washed with EtOAc.
• TFA (5.55 g, 48.7 mmol) was added to 7-((4-methoxybenzyl)(methyl)amino)-3-(5- amino-2-chloro-4-fluorophenyl)-l-isopropyl-l,6-naphthyridin-2(lH)-one (0.78 g, 1.62 mmol) and the reaction was stirred for 90 min at RT. Water (50 mL) was added and the reaction mixture was carefully treated with solid Na 2 C03 until it was faintly basic.
• Example A12 A suspension of Example A3 (1.50 g, 4.26 mmol) in 2- methoxyethylamine (3 mL, 34.51 mm) was heated at 120°C for 12 h. The reaction mixture was diluted with water and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na 2 S0 4 ), and concentrated to provide 3-(5-amino-2-chloro-4- fluorophenyl)-l-ethyl-7-(2-methoxyethylamino)-l,6-naphthyridin-2(lH)-one (1.56 g, 94 % yield) as a white solid.
• 1H NMR 400 MHz, DMSO-d 6 ): ⁇ 8.36 (s, 1 H), 7.65 (s, 1 H), 7.18
• Example A13 A mixture of Example C5 (2.191 g, 7.94 mmol), Example Bl (1.538 g, 8.33 mmol) and KF on alumina (40 wt%) (9.22 g, 63.5 mmol) in DMA (40 mL) was sonicated for 2 h. The mixture was filtered through a shallow bed of silica gel and rinsed well with EtOAc. The filtrate was washed with satd.
• Example A14 A suspension of Example A13 (1.50 g, 3.78 mmol) in dioxane (15 mL) was treated with methylamine (40% in water) (26.4 mL, 303 mmol) in a pressure tube and heated to 100°C overnight. The mixture was cooled to RT, treated with a large amount of brine, then diluted with EtOAc until all of the solids dissolved. The layers were separated, the aqueous layer extracted with additional EtOAc (lx) and the combined organics were washed with satd. NaHC0 3 (lx), dried (MgS0 4 ) and concentrated to dryness.
• Example Al 5 To a solution of Example A3 (1.00 g, 2.84 mmol) in DMF (10 mL) was added N,N-dimethylethanediamine (0.250 g, 2.84 mmol) and the resulting reaction mixture was heated at 100°C for 36 h. The reaction mixture was diluted with water and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (MgS0 4 ), and the solvent evaporated.
• Example A16 To a solution of Example A3 (1.00 g, 2.84 mmol) in DMF (10 mL) was added N,N-dimethylpropaneamine (0.870 g, 8.52 mmol) and the resulting reaction mixture was heated at 100°C for 36 h. The mixture was diluted with water and extracted with EtOAc (3x).
• Example A17 A solution of Example A3 (0.25 g, 0.710 mmol) in THF (6 mL) was treated with dimethylamine (2M in THF, 2.84 mL, 5.68 mmol) and heated at 80°C overnight. Additional dimethylamine (2M in THF, 5.68 mL, 1 1.36 mmol) was added over 3 days and the reaction mixture was heated at 80° C. The mixture was partitioned between DCM and satd. NaHC0 3 and extracted with DCM (3x). The combined organic extracts were dried (MgS0 4 ) and evaporated.
• Example A18 To a solution of Example Bl (19 g, 103.3 mmol) and Example C4 (20.3 g, 103.3 mmol) in DMF (150 mL) was added K 2 C0 3 (28.5 g, 206.6 mmol), and the reaction mixture was heated at 90°C overnight. The mixture was poured into water (300 mL), stirred at RT for 10 min and the resulting precipitate collected by filtration, washed with water and dried to give 3-(5-amino-2,4-difluoro-phenyl)-7-chloro-l-ethyl-lH- [l,6]naphthyridin-2-one (22 g, 65% yield).
• Example A19 To a suspension of Example A18 (0.180 g, 0.536 mmol) in dioxane (5 mL) was added 2-methoxyethylamine (0.462 mL, 5.36 mmol) and the mixture was heated at 100°C for 20 h. Solvent from the reaction mixture was evaporated and the residue was stirred with water (50 mL). The solids were filtered, washed and dried to provide 3-(5-amino-2,4-difluorophenyl)-l-ethyl-7-(2-methoxyethylamino)-l,6-naphthyridin-2(lH)- one (0.185g, 92% yield) as a white solid. MS(ESI) m/z : 375.1 [M+H] + .
• Example A20 A mixture of Example B2 (5 g, 25 mmol), Example CI (5.3 g, 25mmol) and Cs 2 C0 3 (21.4 g, 66 mmol) in DMF (50 mL) was heated at 100°C overnight. The solid was removed by filtration and the filter cake was washed with DMF. The organics were concentrated and the residue was purified by silica gel chromatography (EtOAc/pet ether) to give 3 -(5 -amino-4-fluoro-2-methylphenyl)-7-chloro- 1 -isopropyl- 1 ,6-naphthyridin- 2(lH)-one (1.7 g, 20% yield).
• Example A21 A mixture of Example A20 and (4-methoxy-benzyl)-methyl-amine (4.5 g, 30 mmol) was heated to 180°C under a N 2 atmosphere for 8 h. The excess (4- methoxy-benzyl)-methyl-amine was removed under reduced pressure to give the crude product, which was suspended in 50% aqueous acetic acid and stirred for 30 min.
• Example A22 Example A3 (0.50 g, 1.420 mmol), 4-aminotetrahydropyran (0.431 g, 4.26 mmol) and TEA (0.394 mL, 2.84 mmol) were combined in NMP (5 mL) and the mixture was heated at 180°C under microwave irradiation for 6 h. Additional 4- aminotetrahydropyran (0.2 mL) was added and the mixture was heated at 180°C under microwave irradiation for 3 h more. The mixture was quenched with water and extracted with EtOAc (3x).
• Example A23 Example A3 (0.4 g, 1.14 mmol) and 3-methoxypropylamine (0.5 g, 5.69 mmol) were combined in NMP (5 mL) and heated at 120°C for 24 h. The mixture was poured in water, extracted with EtOAc (2x) and the combined organics were washed with brine, dried (Na 2 S0 4 ), concentrated to dryness and purified by silica gel chromatography (MeOH/DCM) to afford 3-(5-amino-2-chloro-4-fluorophenyl)-l-ethyl-7-(3- methoxypropylamino)-l,6-naphthyridin-2(lH)-one (409 mg, 89% yield) as an orange solid.
• Example A24 A solution of Example C4 (5 g, 23.2 mmol), Example B2 (4.6 g, 23.2 mmol) and CS 2 CO 3 (15g, 2eq) in DMF were heated at 80°C overnight. The mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 S0 4 ), concentrated to dryness and purified by silica gel chromatography to give 3-(5-amino-2,4-difluorophenyl)-7-chloro-l-isopropyl-l,6-naphthyridin-2(lH)-one (4 g, 49% yield). MS (ESI) m/z: 350.2 [M + H] + .
• Example A25 A mixture of Example A24 (4 g, 11.5 mmol) and methylamine (30mL) was heated to 100°C in a sealed vessel for 12 h, then cooled to RT. The mixture was concentrated and residue was washed with EtO Ac to give 3-(5-amino-2,4-difluorophenyl)-l- isopropyl-7-(methylamino)-l,6-naphthyridin-2(lH)-one (3.5 g, 90% yield).
• Example A26 Example A3 (0.150 g, 0.426 mmol) and (S)-(+)-l-methoxy-2- propylamine (0.228 g, 2.56 mmol) were combined in NMP (4 mL) and heated in the microwave at 180°C for 18 h. After cooling, the reaction was diluted with satd. LiCl and extracted with EtO Ac (2x). The combined organics were washed successively with satd. LiCl (lx), H 2 0 (lx), and brine (lx), dried (MgS0 4 ), filtered and evaporated.
• Example A27 A solution of Example A6 (500 mg, 1.507 mmol) and cyclopropylamine (860 mg, 15.07 mmol) in EtOH (15 mL) was heated at 100°C in a sealed vessel. After 20 h the reaction mixture was treated with additional cyclopropylamine (860 mg, 15.07 mmol) and catalytic DMAP (10 mg) and heated at 100°C for 23 h, then 115°C for 10 days. The mixture was cooled to RT, concentrated to dryness and the resulting residue dissolved in EtO Ac (30 mL) and washed successively with water (30 mL), satd. NaHC0 3 (30 mL) and brine (30 mL).
• Example A28 To a suspension of Example A6 (0.500 g, 1.507 mmol) in dioxane (10 mL) was added 2-methoxyethylamine (2 mL, 23.22 mmol) and the mixture was heated at 100°C for 40 h. Solvent from the reaction mixture was evaporated and the residue was diluted with water (50 mL) and extracted with EtOAc (3x).
• Example A29 A solution of Example A13 (0.500 g, 1.261 mmol) and 2-methoxy ethylamine (0.947 g, 12.61 mmol) in NMP (5 mL) was heated at 120°C. After 4 h the reaction mixture was cooled and partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with additional EtOAc (lx). The combined organic layers were washed with brine, dried and the solvent evaporated to provide 3-(5-amino-2-bromo-4-fluorophenyl)- 1 -ethyl-7-(2-methoxyethylamino)- 1 ,6-naphthyridin-
• Example A30 To a solution of Example A3 (2.0 g, 5.7 mmol) in NMP (10 mL) was added tetrahydro-furan-3-ylamine (1.5 g, 17.2 mmol) and DBU (1.7 g, 11.4 mmol). Nitrogen was bubbled through the mixture for 5 min and then it was heated in the microwave at 180°C for 1 h. The reaction mixture was cooled to RT, poured into water and extracted with EtOAc (3x).
• Example A31 Example A13 (0.165 g, 0.416 mmol) and 2-(thiomethyl)ethylamine (0.38 g, 4.16 mmol) were combined in NMP (2 mL) and the solution was heated in the microwave at 180°C for 5 h. The mixture was poured into water (30 mL) and the resultant suspension was filtered, washed with water and dried to afford 3-(5-amino-2-bromo-4- fluorophenyl)- 1 -ethyl-7-(2-(methylthio)ethylamino)- 1 ,6-naphthyridin-2( 1 H)-one (0.19 g, 100% yield) as an off-white solid.
• Example A32 Example A13 (2.5 g, 6.35 mmol) and 4-methoxybenzylamine (50 mL) were combined and heated at 140°C overnight. The reaction mixture was cooled to RT, then poured into water. The resulting solid was collected via filtration, dried and purified by silica gel chromatography (EtO Ac/pet ether) to give 7-(4-methoxybenzylamino)-3-(5-amino- 2-bromo-4-fluorophenyl)-l -ethyl- l ,6-naphthyridin-2(lH)-one (2.5 g, 81% yield).
• Example A33 Example A32 (2.5 g, 13.8 mmol) in TFA (30 mL) was stirred at 50-60°C for 2 days. The mixture was concentrated, dissolved in EtOAc (100 mL) and washed with satd. NaHC0 3 (3x), then brine (3x). The organic layer was dried with Na 2 S0 4 , and concentrated to obtain crude product. Hydrochloric acid (6 M, 100 mL) was added to the residue and the solution was washed with EtOAc (3x). The aqueous layer was neutralized with satd. NaHC0 3 and then extracted with EtOAc (3x).
• Example A34 A solution of Example A6 (2.5 g, 7.5 mmol) and 4- methoxybenzylamine (30 mL) was refluxed at 140°C for 2 h. After cooling to RT, the reaction mixture was poured into a 20% aq. solution of acetic acid and stirred for 0.5 h. The mixture was filtered to provide 7-(4-methoxybenzylamino)-3-(5-amino-4-fluoro-2- methylphenyl)- 1 -ethyl- 1 ,6-naphthyridin-2( 1 H)-one.
• Example A35 Example A9 (2 g, 4.4 mmol) in TFA (10 mL) was stirred at 60°C overnight, cooled to RT, added to water (10 mL) and extracted with EtOAc (3x). The combined organics layers were washed with brine, dried over Na 2 S0 4 , concentrated in vacuo, and purified by silica gel chromatography to afford 7-amino-3-(5-amino-2-chloro-4- fluorophenyl)-l-ethyl-l ,6-naphthyridin-2(lH)-one (870 mg, 59 % yield).
• Example A36 A solution of Example A18 (1 g, 3 mmol) in (4- methoxyphenyl)methanamine (10 mL) was heated at 130°C overnight. The mixture was cooled to RT, poured into a mixture of 1 : 1 acetic acid and water (10 mL), stirred for 30 minutes, and extracted with EtOAc (2x).
• Example A37 To a solution of Example B3 (1 g, 5.5 mmol) and Example C5
• Example A38 A solution of Example Bl (6.0 g, 0.033 mol), ethyl 2-(3-amino-4- fluorophenyl)acetate (6.4 g, 0.033 mol) and K 2 C0 3 (9.17 g, 0.066 mol) in DMF (100 mL) was heated to 80°C overnight. The reaction mixture was poured into the water and extracted with EtOAc (3x).
• Example A39 Using the 2-step procedure of Example A4 and A5, Example A38 (0.85 g, 2.7 mmol) and 4-methoxybenzylmethylamine (10 mL) were combined to provide 3- (3-amino-4-fluorophenyl)-l-ethyl-7-(methylamino)-l,6-naphthyridin-2(lH)-one (0.45 g, 32% yield, 2 steps).
• Example A40 KF/A1 2 0 3 (40 wt %, 10 g, 69 mmol) was added to a solution of Example B2 (6 g, 30 mmol) and ethyl (3-amino-4-fluorophenyl)acetate (6 g, 30 mmol) in DMA (80 mL) and stirred at RT for 1 h. The mixture was filtered and the filtrate was concentrated under vacuum.
• Example A41 Example C2 (3 g, 12.9 mmol), Example B3 (2.2 g, 12.9 mmol) and KF/AI 2 O 3 (40 %, 6 g, 41 mmol) were combined in DMA (40 mL) and the resultant mixture was stirred at RT for 1 h. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was washed with Et 2 0 to give 3-(5-amino-2-chloro-4-fluorophenyl)-7- chloro-1 -methyl- l,6-naphthyridin-2(lH)-one (2.6 g, 60% yield).
• Example A42 Example B3 (3.2 g, 18.8 mmol), Example C6 (4.0 g, 18.8 mmol) and Cs 2 C0 3 (12.3 g, 37.6 mmol) were combined in DMF (80 mL) and heated to 80°C for 4 h. The reaction mixture was poured into water (600 mL) and the precipitate was collected by filtration and dried under reduced pressure to give 3-(5-amino-2-chlorophenyl)-7-chloro-l- methyl-l,6-naphthyridin-2(lH)-one (5.0 g, 83% yield).
• Example A43 A solution of Example B3 (2 g, 11.8 mmol) in DMA (40 mL) was treated with Example CI (2.5 g, 11.8 mmol), followed by KF/A1 2 0 3 (40 wt %, 10 g, 68 mmol) and stirred at RT for 2 h. The mixture was filtered, the filtrate poured into water and the precipitate was collected by filtration and dried to give 3-(5-amino-4-fluoro-2- methylphenyl)-7-chloro-l-methyl-l,6-naphthyridin-2(lH)-one (2.5 g, 69% yield).
• Example A44 Example B3 (2 g, 9.3 mmol), Example C4 (1.6 g, 9.3 mmol) and KF/AI 2 O 3 (40 %, 5 g, 34.4 mmol) were combined in DMA and stirred for 10 min. The reaction mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 S0 4 ) and concentrated in vacuo. The residue was purified by chromatography to give 3-(5-amino-2,4-difluorophenyl)-7-chloro-l -methyl- 1,6- naphthyridin-2(lH)-one (2 g, 68% yield).
• Example A45 A solution of 4-chloro-2-fluoroaniline (5.0 g, 34.3 mmol) in acetic acid (3 mL) was treated with acetic anhydride (6.45 mL, 68.7 mmol) and stirred at RT for 2 h. The mixture was poured onto ice water, stirred for 2 h and the resulting solid collected via filtration and dried to afford N-(4-chloro-2-fluorophenyl)acetamide (6.12 g, 95% yield). 1H
• HC1 gas was bubbled into 0°C EtOH (30 mL), added to N-(4-chloro-3- (cyanomethyl)-2-fluorophenyl)acetamide (0.28 g, 1.235 mmol) and heated at 80°C for 7 h. The mixture was cooled to RT, concentrated to dryness and the residue neutralized with satd. NaHC0 3 .
• Example A46 Using the three-step procedure of Example A42, Example Bl (3.5 g, 18.8 mmol), Example C6 (4.0 g, 18.8 mmol), Cs 2 C0 3 (12.3 g, 37.6 mmol), 4- methoxybenzylmethylamine (3.6 g, 23.5 mmol) and TFA (10 mL, 134 mmol) were combined to provide 3 -(5 -amino-2-chlorophenyl)- 1 -ethyl-7-(methylamino)- 1 ,6-naphthyridin-2( 1 H)-one (1.68 g, 27% yield over 3 steps).
• Example A47 A bi-phasic mixture of Example A4 (1.00 g, 2.142 mmol) in EtOAc (25 mL) and satd. NaHC0 3 (25 mL) was treated with isopropenyl chloroformate (516 mg, 4.28 mmol) and stirred vigorously at RT for 3 h. Hexane (10 mL) was added and the resulting solid collected via filtration and dried.
• Example A48 A biphasic solution of Example A2 (300 mg, 0.919 mmol) in EtOAc (10 mL) and satd. NaHC0 3 (10 mL) was treated with isopropenyl chloroformate (138 mg, 1.149 mmol) and stirred at RT for 6 h. Additional isopropenyl chloroformate (50 ⁇ ) was added and the mixture stirred at RT overnight.
• Example A49 A 0°C solution of Example A14 (0.75 g, 1.917 mmol) in a biphasic mixture of 1 : 1 : 1 EtOAc/THF/satd. NaHC0 3 (90 mL) was treated with isopropenyl chloroformate (0.220 mL, 2.013 mmol), allowed to warm to RT and stirred overnight. Additional isopropenyl chloroformate (0.220 mL, 2.013 mmol) was added, the mixture stirred at RT for 3 h, then placed in the refrigerator overnight.
• Example A50 A solution of Example 21 (0.1 g, 0.221 mmol) in pyridine (5 mL) was treated with isopropenyl chloro formate (0.027 mL, 0.243 mmol) and stirred at RT overnight. Water was added and the resulting solid was collected via filtration and dried to afford prop-1 -en-2-yl (3-(2-chloro-4-fluoro-5-(3-phenylureido)phenyl)- 1 -ethyl-2-oxo- 1 ,2- dihydro-l,6-naphthyridin-7-yl)carbamate (105 mg, 89% yield).
• Example A51 A suspension of Example A5 (0.154 g, 0.444 mmol) in EtOAc (2.5 mL) was treated with satd. NaHC0 3 (2.5 mL) and isopropenyl chloroformate (0.046 mL, 0.422 mmol) and the biphasic mixture stirred vigorously at RT for 3.5 h. Additional isopropenyl chloroformate (20 ⁇ ) was added and the mixture was stirred at RT overnight. The mixture was diluted with additional EtOAc and satd. NaHC0 3 and the layers separated. The organic layer was washed with brine, dried over MgS0 4 and concentrated to dryness.
• Example A52 A mixture of Example A10 (200 mg, 0.546 mmol) and pyridine (173 mg, 2.184 mmol) in THF (5 mL) was treated with 3 -fluorophenyl isocyanate (90 mg, 0.655 mmol) and stirred at RT overnight. The mixture was treated with water and EtOAc and most of the aqueous layer was removed. DMF was added, the mixture concentrated to dryness and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA). The organics were removed under reduced pressure and the aqueous residue was treated with satd. NaHC0 3 and allowed to stand at RT.
• Example A53 A suspension of Example A6 (0.161 g, 0.485 mmol) in EtOAc (2.5 mL) was treated with satd. NaHC0 3 (2.5 mL) followed by isopropenyl chloroformate (0.080 mL, 0.728 mmol) and the bi-phasic mixture stirred vigorously at RT for 2 h.
• Example A54 A solution of Example A6 (0.200 g, 0.603 mmol) and TEA (0.126 mL, 0.904 mmol) in THF (6 mL) was treated with phenyl isocyanate (0.066 mL, 0.603 mmol and stirred at RT overnight. The resulting solid was collected via filtration and dried to afford 1 -(5-(7-chloro-l -ethyl-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3-yl)-2-fluoro-4- methylphenyl)-3-phenylurea (211 mg, 78% yield).
• Example A55 A mixture of Example A10 (700 mg, 1.911 mmol) and pyridine (605 mg, 7.65 mmol) in THF (15 mL) was treated with phenyl isocyanate (250 mg, 2.103 mmol) and stirred at RT for 19 h. The mixture was diluted with EtOAc, washed with satd. NaHC0 3 , then brine, dried over Na 2 S0 4 , concentrated to dryness and purified via reverse- phase chromatography (MeCN/H 2 0 with 0.1% TFA). The organics were removed under reduced pressure, the aqueous residue treated with satd. NaHC0 3 and allowed to stand at RT.
• Example A56 A solution of Example A6 (0.200 g, 0.603 mmol) and TEA (0.126 mL, 0.904 mmol) in THF (6 mL) was treated with 3 -fluorophenyl isocyanate (0.083 ml, 0.723 mmol) and stirred at RT for 4 h. The mixture was concentrated to dryness and purified via silica gel chromatography (EtO Ac/Hex). The material was treated with DCM and the solid collected via filtration.
• Example A57 A mixture of Example A34 (0.3 g, 0.960 mmol), phenyl isocyanate (0.137 g, 1.153 mmol) and TEA (0.134 ml, 0.960 mmol) in THF (5 mL) was stirred at RT for 4 h. The mixture was treated with 30% EtO Ac/Hex, stirred for several minutes and the resulting solid was collected via filtration and dried to afford l-(5-(7-amino- 1 -ethyl-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3-yl)-2-fluoro-4-methylphenyl)-3-phenylurea
• Example Bl A 0°C solution of Example C3 (4.4 g, 20 mmol) in MeCN (50 mL) was treated drop-wise with a solution of 65% ethylamine in water (2.7 g, 39 mmol), warmed to RT and stirred. The reaction was concentrated and the residue was washed with water to give ethyl 6-chloro-4-(ethylamino)nicotinate (3.9 g, 91% yield).
• Example B2 Using the three-step procedure of Example Bl, Example C3 (20 g, 91 mmol) and isopropylamine (60 % in water, 18 g, 182 mmol) were converted to 6-chloro- 4-(isopropylamino)nicotinaldehyde (16 g, 81% yield).
• Example B3 A 0°C solution of ethyl 4,6-dichloronicotinate (5 g, 22.8 mmol) in MeCN (30 mL) was treated drop-wise with aqueous methylamine (65%>, 5.2 g, 45.6 mmol), warmed to RT and stirred for 8 h. The mixture was concentrated to dryness, the residue suspended in H 2 0 and extracted with EtOAc (3x). The combined extracts were washed with brine, dried (MgS0 4 ) and concentrated to give ethyl 6-chloro-4-(methylamino)nicotinate (4 g, 82%o yield), which was used in the next step without further purification.
• Example CI To stirring fuming HN0 3 (90 wt%, 30.0 mL, 643 mmol) at -15°C was added 4-fluoro-2-methylphenylacetic acid (15 g, 89.2 mmol) in portions such that the internal temperature remained below -10°C. After completing the addition the reaction was stirred with warming to 5°C over 15 min.
• Example C2 HN0 3 (10.35 g, 98.6 mmol) was added drop-wise to a -10°C solution of 2-(2-chloro-4-fluorophenyl)acetic acid (16.9 g, 89.6 mmol) in cone. H 2 S0 4 (60 mL), stirred at 0°C for 10 min, then carefully poured into ice water. The off- white solid was collected by filtration and dried to give 2-(2-chloro-4-fluoro-5-nitrophenyl)acetic acid (20.5 g, 98% yield).
• Example C3 3-Oxo-pentanedioic acid diethyl ester (101 g, 0.5 mmol), triethyl ortho formate (81.4 g, 0.55mol) and acetic anhydride (102 g, 1 mol) were combined and heated to 120°C for 2 h. The resulting mixture was cooled to RT and dissolved in DCM (1 L). After further cooling to 0°C, ammonia (30%, 80 mL) was added and the reaction mixture was allowed to warm to RT overnight. The product was extracted with water (2x) and the aqueous layer was acidified to pH 5 with cone. HC1.
• Ethyl 4,6-dihydroxynicotinate 60 g, 0.328 mol was added slowly to POCl 3 (500 mL), then heated to reflux for 2 h. The resulting mixture was distilled under reduced pressure to remove excess POCl 3 . The residue was poured into ice water and stirred for 30 minutes before extracting with EtOAc (3x). The combined extracts were washed with brine, dried (MgS0 4 ) and concentrated in vacuo to give ethyl 4,6-dichloronicotinate (65 g, 90%>, yield).
• Example C4 A 0°C solution of (2,4-difluoro-phenyl)acetic acid (14.5 g, 0.084 mol) in H 2 S0 4 (60 niL) was treated drop-wise with 69% HN0 3 (6 niL), stirred at 0°C for 35 min, then poured into ice water. The aqueous layer was extracted with EtOAc, and the organic extracts were washed with brine, dried (Na 2 S0 4 ), concentrated in vacuo and purified by silica gel chromatography to give (2,4-difluoro-5-nitro-phenyl)acetic acid (16 g, 88% yield).
• Example C5 Nitric acid (16.00 mL, 322 mmol) was cooled to -15°C and treated portion-wise with 2-bromo-4-fluorophenylacetic acid (10.00 g, 42.9 mmol) maintaining an internal temperature of -10°C to -5°C. Once the addition was complete the mixture was warmed to 5°C over -15 minutes, poured onto ice (200 mL), stirred vigorously until all of the ice melted, and then filtered and rinsed with water.
• Example C6 A mixture of (2-chlorophenyl)acetic acid (15 g, 88 mmol) in cone. H 2 S0 4 (100 mL) was cooled to -20°C and treated drop-wise with cone. HN0 3 (9.4 g, 97 mmol). The resulting mixture was stirred at -20°C for 0.5 h, poured into the ice-water, and extracted with EtO Ac (3x). The combined organics were washed with brine, dried over Na 2 S0 4 and concentrated in vacuo to give (2-chloro-5-nitrophenyl)acetic acid (15 g, 79%> yield).
• 1H NMR 400 MHz, DMSO-d 6 ): ⁇ 8.58 (s, 1 H), 8.35 (m, 1 H), 7.96 (m, 1H), 4.12 (s, 2 H).
• Example Dl A -20°C mixture of N-methylpiperazine (233 ⁇ , 2.097 mmol) and DIEA (452 mg, 3.49 mmol) in THF (12 mL) was treated drop-wise with a solution of t-butyl (3-bromomethyl)phenylcarbamate (500 mg, 1.747 mmol) in THF (3 mL) and stirred overnight as the cooling bath expired. The mixture was diluted with EtOAc, washed with satd.
• Example D2 A mixture of 2-fluoro-5-nitrotoluene (0.750 g, 4.83 mmol), NBS (1.549 g, 8.70 mmol) and AIBN (0.159 g, 0.967 mmol) in trifiuorotoluene (15 ml) was heated to reflux overnight. The mixture was cooled RT, the solids removed via filtration and the filtrate concentrated to dryness and purified via silica gel chromatography (EtO Ac/Hex) to afford -80% pure 2-(bromomethyl)-l-fluoro-4-nitrobenzene (956 mg, 63% yield).
• the resulting material was treated with THF (20 mL), sonicated for several hours and the solvent decanted from the solids.
• the solids were treated with additional THF (20 mL), sonicated again and the solvent decanted.
• the solids were treated with THF (20 mL) for a third time, stirred vigorously overnight, then the liquid was decanted.
• the combined decanted liquids were concentrated to dryness, treated with DCM, filtered to remove solids and concentrated to dryness to afford very hydroscopic 4-fluoro-3- ((4-methylpiperazin-l-yl)methyl)aniline (382 mg, 75% yield).
• Example D3 A mixture of l-fluoro-2-methyl-4-nitrobenzene (2.5 g, 16.12 mmol) and NBS (3.16 g, 17.73 mmol) in trifluorotoluene (45 mL) was treated with AIBN (66 mg, 0.403 mmol) and heated at 80°C overnight. The mixture was cooled to RT, the solids removed via filtration and the filtrate concentrated to dryness.
• Example 1 Using general method B, 1-isocyanatonaphthalene (0.051 g, 0.3 mmol) and Example A2 (0.1 g, 0.3 mmol) were combined to afford l-(5-(l-ethyl-7-(methylamino)- 2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)-2-fluoro-4-methylphenyl)-3 -(naphthalen- 1 -yl)urea as a white solid (0.115 g, 77% yield).
• Example 2 Using general method B, 1-isocyanatonaphthalene (0.045 g, 0.26 mmol) and Example A39 (0.1 g, 0.3 mmol) were combined to afford l-(5-(l-ethyl-7- (methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)-2-fluorophenyl)-3 -(naphthalen- 1 - yl)urea as a white solid (0.062 g, 48% yield).
• Example 3 Using general method B, 1-isocyanatobenzene (0.05g, 0.420 mmol) and Example A5 (0.146 g, 0.420 mmol) were combined to provide l-(4-chloro-5-(l-ethyl-7- (methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
• Example 4 Using general method A, 2,3-difluorobenzoic acid (0.100 g, 0.633 mmol) and Example A5 (0.219 g, 0.633 mmol) were combined to provide l-(4-chloro-5-(l- ethyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2-fluorophenyl)-3-(2,3- difluorophenyl)urea (0.172g, 54% yield).
• Example 5 Using general method B, phenyl isocyanate (0.036 g, 0.302 mmol) and Example A40 (0.1 g, 0.302 mmol) were combined to provide l-(2-fluoro-5-(l-isopropyl-7- (methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)phenyl)-3 -phenylurea (0.94g, 70% yield).
• Example 6 Using general method B, 1-isocyanatonaphthalene (0.05 g, 0.29 mmol) and Example A5 (0.1 g, 0.29 mmol) were combined to afford l-(4-chloro-5-(l-ethyl-7- (methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)-2-fluorophenyl)-3 -(naphthalen- 1 - yl)urea as a white solid (0.121 g, 79% yield).
• Example 7 Using general method B, phenyl isocyanate (0.050 g, 0.420 mmol) was reacted with Example A41 (0.070 g, 0.210 mmol) in EtOAc (2 mL) for 13 h to provide l-(4- chloro-2-fluoro-5-(l-methyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3- yl)phenyl)-3-phenylurea (0.080g, 84% yield).
• L H NMR 400 MHz, DMSO-d 6 ): ⁇ 9.08 (s, 1
• Example 8 Using general method B, 1-isocyanatonaphthalene (0.050 g, 0.296 mmol) was reacted with Example A41 (0.070 g, 0.210 mmol) in EtOAc (2 mL) at RT for 13 h to provide l-(4-chloro-2-fluoro-5-(l-methyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6- naphthyridin-3-yl)phenyl)-3-(naphthalen-l-yl)urea (0.07g, 67 % yield).
• Example 9 Using general methode B, 3-isocyanatobenzonitrile (0.050 g, 0.347 mmol) was reacted with Example A41 (0.070 g, 0.210 mmol) in EtOAc (2 mL) for 13 h to provide 1 -(4-chloro-2-fluoro-5-( 1 -methyl-7-(methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6- naphthyridin-3-yl)phenyl)-3-(3-cyanophenyl)urea (0.090g, 90% yield). !
• Example 10 Using general method A, 2,3-difluorobenzoic acid (0.071 g, 0.449 mmol), TEA (0.091 g, 0.898 mmol), DPPA (0.124 g, 0.449 mmol) and Example A41 (0.100 g, 0.299 mmol) were combined to provide l-(4-chloro-2-fluoro-5-(l-methyl-7- (methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)phenyl)-3-(2,3-difluorophenyl)urea
• Example 11 Using general method B, 3-isocyanatobenzonitrile (0.070 g, 0.486 mmol) was reacted with Example A42 (0.070 g, 0.222 mmol) in EtOAc (2 mL) for 13 h to provide l-(4-chloro-3-(l-methyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3- yl)phenyl)-3-(3-cyanophenyl)urea (55 mg, 54% yield).
• 1H NMR 400 MHz, DMSO-d 6 ): ⁇
• Example 12 Using general method B, 3-isocyanatobenzonitrile (0.032 g, 0.224 mmol) was reacted with Example A39 (0.070 g, 0.224 mmol) in EtOAc (5 mL) for 20 h to provide l-(3-cyanophenyl)-3-(5-(l-ethyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6- naphthyridin-3-yl)-2-fiuorophenyl)urea (17 mg, 17% yield).
• Example 13 Using general method A, benzothiophene-3-carboxylic acid (103 mg, 0.576 mmol), TEA (194 mg, 1.921 mmol), DPPA (165 mg, 0.600 mmol) and Example A43 (0.100 g, 0.299 mmol) were combined to provide l-(benzo[b]thiophen-3-yl)-3-(2-fluoro-4- methyl-5-(l -methyl-7-(methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3-yl)phenyl)urea (140 mg, 59% yield).
• Example 14 Using general method A, benzo[b]thiophene-3-carboxylic acid (0.101 g, 0.569 mmol), TEA (0.144 g, 1.423 mmol), DPPA (0.196 g, 0.711 mmol) and Example A44 (0.150 g, 0.474 mmol) were combined to provide l-(benzo[b]thiophen-3-yl)- 3-(2,4-difluoro-5-(l-methyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3- yl)phenyl)urea (177 mg, 76% yield).
• Example 15 3 -Fluorophenyl isocyanate (81 mg, 0.444 mmol) was added to a solution of Example A7 (200 mg, 0.444 mmol) in THF (5 mL) and the mixture was stirred at RT overnight. The reaction was treated with additional isocyanate (10 mg) and stirred at RT for a further 4 h. The mixture was diluted with EtOAc, washed successively with water, satd. NaHC0 3 , and brine, dried (Na 2 S0 4 ), concentrated in vacuo, purified by reverse phase chromatography (MeCN/water with 0.1% TFA) and partially concentrated to give an aqueous solution. The solution was diluted with satd.
• Example 16 Phenyl isocyanate (58 mg, 0.488 mmol) was added to a solution of Example A7 (200 mg, 0.444 mmol) and pyridine (140 mg, 1.776 mmol) in THF (5 mL) and the mixture was stirred at RT overnight. The mixture was diluted with EtOAc, water and satd.
• Example 17 Using a procedure analogous to Example 16, Example A7 (200 mg, 0.444 mmol) and 3-chlorophenyl isocyanate (58 mg, 0.488 mmol) were combined to give 1- (5-(7-((4-methoxybenzyl)(methyl)amino)- 1 -ethyl-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3-yl)- 2,4-difluorophenyl)-3-(3-chlorophenyl)urea (229 mg, 85% yield). MS (ES-API) m/z: 604.2 [M+H] + .
• Example 18 Using a procedure analogous to Example 16, Example A7 (200 mg, 0.444 mmol) and 3-cyanophenyl isocyanate (70 mg, 0.488 mmol) were combined to give 1- (5-(7-((4-methoxybenzyl)(methyl)amino)- 1 -ethyl-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3-yl)- 2,4-difluorophenyl)-3-(3-cyanophenyl)urea (240 mg, 91% yield). MS (ES-API) m/z: 595.2 [M+H] + .
• Example 19 Using general method A, benzo[b]thiophene-3-carboxylic acid (113 mg, 0.636 mmol), TEA (245 mg, 2.422 mmol), DPPA (200 mg, 0.727 mmol) and Example A8 (200 mg, 0.605 mmol) were combined and purified via precipitation to provide 1- (benzo[b]thiophen-3-yl)-3-(5-(l-ethyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin- 3-yl)-2,4-difluorophenyl)urea (153 mg, 50% yield).
• Example 20 DMF (0.2 mL) and 3 -fluorophenyl isocyanate (67 mg, 0.486 mmol) were added to a slurry of Example A9 (200 mg, 0.442 mmol) and pyridine (140 mg, 1.766 mmol) in THF (5 mL) and the mixture was stirred at RT overnight. The mixture was diluted with EtOAc and water, warmed, then cooled to RT and the resulting solid collected via filtration.
• Example 21 DMF (0.2 mL) and phenyl isocyanate (58 mg, 0.486 mmol) were added to a slurry of Example A9 (200 mg, 0.442 mmol) and pyridine (140 mg, 1.766 mmol) in THF (5 mL) and the mixture stirred at RT overnight. The mixture was diluted with EtOAc and water and warmed. The organic phase was separated, washed with brine, dried (Na 2 S0 4 ), concentrated in vacuo, purified by reverse phase chromatography (MeCN/water with 0.1%) TFA) and concentrated to give an aqueous residue. The aqueous residue was treated with satd. NaHC0 3 and allowed to precipitate.
• Example 22 Example All (0.12 g, 0.33 mmol), TEA (0.046 mL, 0.33 mmol) and phenyl isocyanate (0.044 g, 0.36 mmol) were combined in THF (4 mL), stirred at RT for 20 h, concentrated in vacuo and purified by silica gel chromatography (EtOAc/DCM) to afford 1 -(4-chloro-2-fluoro-5-(l -isopropyl-7-(methylamino)-2-oxo- 1 ,2-dihydro-l ,6-naphthyridin-3- yl)phenyl)-3-phenylurea (97 mg, 61% yield) as a white solid.
• Example 23 A solution of pyridine (0.248 mL, 3.06 mmol) and phenyl isocyanate (0.100 mL, 0.919 mmol) in DMF (0.4 mL) was added to a solution of Example A2 (0.25 g, 0.766 mmol) in THF (5 mL) and the mixture was stirred at RT.
• Example 24 A 0°C solution of Example A5 (200 mg 0.58 mmol) and pyridine (68 mg, 0.87 mmol) in THF (20 mL) was treated with l-fiuoro-3-isocyanato-benzene (80 mg, 0.58 mmol), warmed to RT and stirred for 3 h.
• Example 25 Using a procedure analogous to Example 24, Example A5 (400 mg 1.16 mmol) and l-fluoro-2-isocyanato-benzene (158 mg, 1.16 mmol) were converted to l-[4- chloro-5- (l-ethyl-7-methylamino-2-oxo-l,2-dihydro-[l,6]naphthyridin-3-yl)-2-fluoro- phenyl]-3-(2-fluoro-phenyl)-urea (144 mg, 26% yield).
• Example 26 A solution of Example A45 (0.09 g, 0.260 mmol) in THF (3 mL) was treated with TEA (0.036 mL, 0.260 mmol) and phenyl isocyanate (0.034 g, 0.285 mmol) and stirred at RT overnight. Additional phenyl isocyanate (0.034 g, 0.285 mmol) was added and the mixture heated at 60°C for 5 h.
• Example 27 A suspension of Example A12 (0.300 g, 0.768 mmol) in EtOAc (6 mL) was treated with phenyl isocyanate (0.091 g, 0.768 mmol), stirred at RT for 13 h and the resulting solid collected by suction filtration. The white solids were stirred in boiling MeCN for 20 minutes followed by stirring at RT for 1 h.
• Example 28 To a suspension of Example A12 (0.300 g, 0.768 mmol) in EtOAc (6 mL) was added 3 -fluorophenyl isocyanate (0.105 g, 0.768 mmol). The mixture was stirred at RT for 13 h and solids from the reaction mixture were collected by suction filtration. The white solids were stirred in refluxing MeCN for 20 minutes, followed by stirring at RT for 1 h.
• Example 29 To a suspension of Example A15 (0.300 g, 0.743 mmol) in EtOAc (6 mL) was added phenyl isocyanate (0.088 g, 0.743 mmol) and the mixture was stirred at RT for 13 h. The solids were filtered, washed and dried to provide l-(4-chloro-5-(7-(2- (dimethylamino)ethylamino)- 1 -ethyl-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3-yl)-2- fluorophenyl)-3-phenylurea (320 mg, 82% yield) as a white solid. MS(ESI) m z : 524.2 [M+H] + .
• Example 30 To a suspension of Example A16 (0.320 g, 0.766 mmol) in EtOAc (6 mL) was added phenyl isocyanate (0.091 g, 0.766 mmol) and the mixture was stirred at RT for 13 h.
• reaction mixture was diluted with EtOAc, filtered, washed and dried to provide l-(4-chloro-5-(7-(3-(dimethylamino)propylamino)-l-ethyl-2-oxo-l,2- dihydro-l,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea dihydrochloride (118 mg, 80%> yield) as a white solid.
• Example 31 A mixture of Example A14 (0.120 g, 0.307 mmol) and TEA (0.043 mL, 0.307 mmol) in THF (3.0 mL) was treated with phenyl isocyanate (0.040 g, 0.337 mmol) and stirred at RT for 4 h. Over the course of the next 4 days the mixture was treated with additional phenyl isocyanate (0.056 mL) and stirred at RT.
• Example 32 Example A5 (0.2 g, 0.577 mmol), benzothiophene-3-carboxylic acid (0.134 g, 0.750 mmol) and TEA (0.322 mL, 2.307 mmol) were suspended in dioxane (5 mL), treated with DPPA (0.186 mL, 0.865 mmol) and heated to 100°C for 3 h.
• Example 33 A solution of Example A46 (0.12 g, 0.365 mmol) in pyridine (3 mL) was treated with phenyl isocyanate (0.044 mL, 0.401 mmol) and stirred at RT overnight. The mixture was concentrated to dryness, the residue treated with MeCN, sonicated and the resulting solid collected via filtration and dried to afford l-(4-chloro-3-(l-ethyl-7- (methylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -y l)phenyl)-3 -phenylurea (166 mg, 102% yield). MS (ESI) m/z: 448.1 [M+H] + .
• Example 34 To a suspension of Example A12 (0.200 g, 0.512 mmol) in EtOAc (5 mL) was added l-fluoro-4-isocyanatobenzene (0.093 g, 0.681 mmol) and the mixture stirred at RT for 16 h.
• Example 35 To a suspension of Example A12 (0.200 g, 0.512 mmol) in EtOAc (5 mL) was added l-fluoro-2-isocyanatobenzene (0.093 g, 0.681 mmol) and the mixture was stirred at RT for 16 h.
• Example 36 To a suspension of Example A19 (0.200 g, 0.534 mmol) in EtOAc (5 mL) was added phenyl isocyanate (0.085 g, 0.710 mmol) and the mixture was stirred at RT for 16 h. The solids were filtered, washed and dried to provide l-(5-(l-ethyl-7-(2- methoxyethylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2,4-difluorophenyl)-3- phenylurea (201 mg, 76% yield) as a white solid.
• Example 37 To a suspension of Example A28 (0.400 g, 1.080 mmol) in EtOAc (10 mL) was added phenyl isocyanate (0.171 g, 1.436 mmol) and the mixture stirred at RT for 16 h. The solids were filtered, washed, and dried to provide l-(5-(l-ethyl-7-(2- methoxyethylamino)-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3 -yl)-2-fluoro-4-methylphenyl)-3 - phenylurea (500 mg, 95% yield) as a white solid. MS(ESI) m/z: 490.2 [M+H] + .
• Example 38 To a suspension of Example A2 (0.09 g, 0.276 mmol) and TEA (0.038 mL, 0.276 mmol) in THF (3 mL) was added 2-fluorophenyl isocyanate (0.042 g, 0.303 mmol) and the mixture stirred at RT for 16 h.
• Example 39 To a solution of Example A23 (0.105 g, 0.26 mmol) and TEA (0.036 mL, 0.26 mmol) in THF (3 mL) was added phenyl isocyanate (0.04 g, 0.337 mmol) and the suspension was stirred at RT for 2 h.
• Example 40 To a suspension of Example A25 (0.300 g, 0.871 mmol) in EtOAc (5 mL) was added 3-fluorophenylisocyanate (0.119 g, 0.871 mmol) and the mixture stirred at RT for 2 h. The solids were filtered, washed and dried to provide l-(2,4-difluoro-5-(l- isopropyl-7-(methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)phenyl)-3-(3- fluorophenyl)urea (0.364 g, 87% yield ) as an off-white solid.
• Example 41 Example A21 (0.20 g, 0.588 mmol) and 3 -fluorophenyl isocyanate (0.081 g, 0.588 mmol) were combined in THF (5 mL), treated with TEA (0.163 mL, 1.175 mmol) and stirred at RT overnight. The solvent was removed and the residue was purified by reverse phase column chromatography (MeCN/H 2 0 with 0.1% TFA). Pure fractions were combined and co-concentrated with MeOH and the remaining aqueous solution was treated with NaHCC"3 and extracted with EtOAc.
• Example 42 Example A22 (0.15 g, 0.360 mmol) and phenyl isocyanate (0.051 g, 0.432 mmol) were combined in THF (5 mL), treated with TEA (0.100 mL, 0.720 mmol) and stirred at RT overnight.
• Example 43 Example A26 (0.13 g, 0.321 mmol) was dissolved in EtOAc (10 mL), treated with phenyl isocyanate (0.037 mL, 0.337 mmol) and stirred at RT overnight.
• Example 44 A solution of Example A2 (300 mg, 0.919 mmol) in pyridine (5 mL) was treated drop-wise with 3 -fluorophenyl isocyanate (139 mg, 1.011 mmol) and stirred at RT. The mixture was diluted with EtOAc and water and the remaining solid was collected via filtration, washed with water and EtOAc and purified by reverse phase chromatography (MeCN/water with 0.1% TFA). The organics were removed under reduced pressure and the aqueous residue was treated with satd. NaHC0 3 (10 mL) and allowed to precipitate.
• Example 45 A solution of Example A27 (124 mg, 0.352 mmol) in pyridine (4 mL) was treated drop-wise with 3 -fluorophenyl isocyanate (51 mg, 0.369 mmol) and stirred at RT. The mixture was diluted with EtOAc and water, the remaining solid collected via filtration, washed with Et 2 0, dried, and purified by reverse phase chromatography (MeCN/water with 0.1% TFA). The organics were removed under reduced pressure and the aqueous residue was treated with satd. NaHC0 3 and extracted with hot EtOAc (2x).
• Example 46 To a solution of Example A3 (2.1 g, 5.96 mmol) in NMP (10 mL) was added l-methyl-piperidin-4-ylamine (1.36 g, 11.9 mmol) and DBU (1.7 g, 11.4 mmol). Nitrogen was bubbled through the mixture for 5 min and then it was heated at 180°C for 12 h. The reaction mixture was cooled to RT, poured into water and extracted with EtOAc (3x).
• Example 47 A solution of Example A30 (150 mg, 0.37 mmol) and pyridine (59 mg, 0.74 mmol) in DCM (3 mL) was treated drop-wise with phenyl isocyanate (53 mg, 0.44 mmol) and stirred at RT under nitrogen overnight. The mixture was filtered and the filter cake was purified by prep-HPLC separation to give l-(4-chloro-5-(l-ethyl-2-oxo-7-(THF-3- ylamino)-l,2-dihydro-l,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea (49 mg, 25% yield).
• Example 48 2-Methylsulfanyl-ethylamine (5 mL) and Example A3 (500 mg, 1.42 mmol) were added to a sealed tube and the mixture was heated at 130°C overnight. The reaction mixture was concentrated under vacuum, treated with water and extracted with EtOAc (3x). The combined organics were washed with brine, dried (Na 2 S0 4 ), and concentrated to give 3-(5-amino-2-chloro-4-fluorophenyl)-l-ethyl-7-(2-
• Example 49 A solution of Example A3 (500 mg, 1.42 mmol), 1-methyl- pyrrolidin-3-ylamine (170 mg, 1.7 mmol) and DBU (383 mg, 2.84 mmol) in NMP (5 mL) was heated with a microwave at 160°C for 2 h. After cooling to RT, the mixture was purified by silica gel chromatography to yield 3-(5-amino-2-chloro-4-fluorophenyl)-l-ethyl-7-(l- methylpyrrolidin-3-ylamino)-l ,6-naphthyridin-2(lH)-one (500 mg, 85% yield) as a yellow oil.
• Example 50 A suspension of Example A14 (0.150 g, 0.383 mmol) and TEA (0.053 mL, 0.383 mmol) in THF (2.5 mL) was treated with 3 -fluorophenyl isocyanate (0.048 mL, 0.422 mmol) and stirred at RT, under an Ar atmosphere, overnight. Additional 3- fluorophenyl isocyanate (0.024 mL, 0.55 eq.) was added, the mixture stirred at RT for 6 h, then treated again with 3 -fluorophenyl isocyanate (1 drop) and the mixture stirred at RT overnight.
• Example 51 To a solution of Example A29 (0.131 g, 1.103 mmol) in DCM (5 mL) was added phenyl isocyanate (0.480 g, 1.103 mmol) and the reaction mixture was stirred at RT. After 2 h the solvent was completely evaporated and the residue was crystallized from MeCN to provide l-(4-bromo-5-(l-ethyl-7-(2-methoxyethylamino)-2-oxo-l,2-dihydro-l,6- naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea (0.433g, 70.8 % yield) as a white solid. MS(ESI) m/z : 554.1/556.1 [M+H] + .
• Example 52 Phenyl isocyanate (0.067 g, 0.56 mmol) was added to a solution of Example A31 (0.19 g, 0.43 mmol) and TEA (0.09 g, 0.87 mmol) in THF (3 mL) and stirred at RT for 1 h.
• Example 53 A suspension of Example A32 (0.278 g, 0.559 mmol) in THF (6 mL) was treated with TEA (0.097 mL, 0.699 mmol) followed by phenyl isocyanate (0.061 mL, 0.559 mmol) and stirred at RT overnight.
• Example 54 Example A35 (0.200 g, 0.601 mmol) was dissolved in THF (6 mL) at RT and treated with TEA (0.109 mL, 0.781 mmol), followed by phenyl isocyanate (0.066 mL, 0.601 mmol). After 2 h, the precipitated solids were collected by filtration and rinsed with THF to obtain l-(5-(7-amino-l-ethyl-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-4- chloro-2-fluorophenyl)-3-phenylurea (200 mg, 74% yield).
• Example 55 A 0°C solution of Example A5 (200 mg, 0.58 mmol) and pyridine (91 mg, 1.16 mmol) in DCM (4 mL) was treated drop-wise with l ,3-difluoro-5-isocyanato- benzene (98 mg, 0.64 mmol) and stirred at RT overnight as the cooling bath expired. The mixture was concentrated to dryness and purified by prep-HPLC.
• Example 56 A mixture of Example A37 (1.3 g, 3.4 mmol), methylamine (25%, 30 mL) and EtOH (5 mL) were heated at 120°C in a pressure vessel for 1 day. The mixture was cooled to RT, the solids collected via filtration, washed with pet ether and dried to give 3-(5-amino-2-bromo-4-fluoro-phenyl)- 1 -methyl-7-methylamino- 1 ⁇ -[ 1 ,6]naphthyridin-2-one (1.06 g, 82.8% yield).
• Example 57 To a solution of Example A33 (300 mg, 0.798 mmol) in DCM (20 mL) was added phenyl isocyanate (284 mg, 2.39 mmol) and TEA (241.7 mg, 2.39 mmol). The mixture was stirred at RT for 3 days and then concentrated and purified by HPLC separation (MeCN/H 2 0 with 0.1%TFA) to give l-(5-(7-amino-l-ethyl-2-oxo-l,2-dihydro- l,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea (20 mg, 5% yield).
• Example 58 To a biphasic solution of 3-fluoroaniline (0.3 mL, 3.12 mmol) in 1 : 1 EtOAc/water (10 mL) was added isopropenyl chloroformate (0.564 g, 4.68 mmol) and NaHC0 3 (1.31g, 15.6 mmol) and the mixture stirred at RT overnight. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were concentrated to dryness and purified by silica gel chromatography (EtO Ac/Hex) to furnish prop-l-en-2-yl 3-fluorophenylcarbamate (125 mg, 21% yield) as a white solid.
• EtO Ac/Hex silica gel chromatography
• the mixture was cooled to RT, concentrated to dryness, treated with MeCN (5 mL) and heated at 70 °C for 5 minutes.
• the solid was collected via filtration, washed with MeCN, treated with MeOH, heated at 50°C and collected via filtration.
• the material was purified via reverse-phase chromatography (MeCN/water with 0.1% TFA).
• Example 60 A suspension of Example A2 (0.096 g, 0.29 mmol) in THF (3 mL) was treated with TEA (0.041 mL, 0.294 mmol) and 3,5-difluorophenyl isocyanate (0.114 g, 0.735 mmol) and stirred at RT for 6 h.
• Example 61 A suspension of Example A2 (0.096 g, 0.29 mmol) in THF (3 mL) was treated with TEA (0.041 mL, 0.294 mmol) and 2,5-difluoro phenyl isocyanate (0.055 g, 0.353 mmol) and stirred at RT for 2 h.
• Example 62 A solution of Example A7 (0.12 g, 0.266 mmol) in dioxane (5 mL) was treated with 2,5-difluorophenyl isocyanate (0.034 mL, 0.293 mmol) and stirred at RT overnight.
• Example 63 A solution of Example A7 (0.12 g, 0.266 mmol) in dioxane (5 mL) was treated with 3,5-difluorophenyl isocyanate (0.038 mL, 0.320 mmol) and stirred at RT overnight. Additional 3,5-difluorophenyl isocyanate (0.038 mL, 0.320 mmol) was added and the mixture stirred for 4 h.
• Example 64 A suspension of Example 57 (135 mg, 0.272 mmol) in ethyl cyanoacetate (2.307 g, 20.40 mmol) was heated at 105°C for 4.5 h, then at 125°C for 2 days. The mixture was treated with NMP (0.3 mL), heated at 125°C for 5 h, then cooled to RT and purified via silica gel chromatography (EtO Ac/Hex). The material was re-purified via silica gel chromatography (THF/Hex), dissolved in 4: 1 MeCN/H 2 0, frozen and lyophilized.
• Example 65 A suspension of Example 21 (0.180 g, 0.398 mmol) in ethyl cyanoacetate (3 ml, 28.1 mmol) was heated at 125°C overnight. The mixture was treated with NMP (0.3 mL), heated at 125°C for 24 h, then cooled to RT and purified via silica gel chromatography (EtO Ac/Hex).
• Example 66 A solution of Example A36 (1 g, 2.3 mmol) in TFA (10 mL) was stirred at 60°C overnight. The solvent was removed and the crude product was treated with satd. NaHC0 3 and extracted with EtOAc (2x). The combined organic extracts were washed with brine, dried over Na 2 S0 4 , and evaporated to yield 7-amino-3-(5-amino-2,4- difluorophenyl)-l -ethyl- l,6-naphthyridin-2(lH)-one (600 mg, 83% yield), which was used in next step without purification.
• Example 67 A solution of Example A3 (0.20 g, 0.568 mmol) in THF (6 mL) was treated with TEA (0.098 mL, 0.710 mmol) followed by 3,5-difluorophenyl isocyanate (0.092 g, 0.596 mmol) and stirred at RT for 2 h. Additional 3,5-difluorophenyl isocyanate (0.14 g, 0.903 mmol) was added and the mixture stirred at RT overnight. More 3,5-difluorophenyl isocyanate (0.25 g, 1.61 mmol) was added and the mixture stirred at RT for 24 h.
• Example 68 A solution of Example A4 (250 mg, 0.535 mmol) in pyridine (2 mL) was treated with 2,5-difluorophenyl isocyanate (91 mg, 0.589 mmol) and stirred at RT overnight. Additional 2,5-difluorophenyl isocyanate (30 ⁇ , 0.256 mmol) was added and stirred at RT for 4 h.
• Example 69 A bi-phasic solution of Example Al (0.15 g, 0.336 mmol) in EtOAc (5 mL) and satd. NaHC0 3 (4.2 mL) was treated with isopropenyl chloroformate (0.061 g, 0.504 mmol) and stirred at RT for 2 h. The layers were separated, the aqueous layer extracted with EtOAc (lx) and the combined organics were washed with brine, dried over Na 2 S0 4 and concentrated to dryness.
• Example 70 A solution of Example A50 (0.105 g, 0.196 mmol) in dioxane (4 mL) was treated with dimethylamine (2M in THF, 4 mL, 8.0 mmol) and stirred at RT overnight. 1-Methylpyrrolidine (0.1 ml) was added and the mixture was stirred at RT for 24 h. Additional 1-methylpyrrolidine (0.1 ml) and dimethylamine (2M in THF, 2 mL, 4.0 mmol) were added and the mixture was stirred at RT for 3 days, then heated at 40°C for 24 h.
• Example 71 A mixture of Example A47 (200 mg, 0.363 mmol), DIEA (188 mg, 1.452 mmol) and 3-chloro-5-fluoroaniline (211 mg, 1.452 mmol) in dioxane (5 mL) was heated at 80°C overnight. The mixture was cooled to RT, treated with EtOAc and satd.
• Example 72 A mixture of Example A47 (200 mg, 0.363 mmol), DIEA (188 mg, 1.452 mmol) and 3-chloro-5-methylaniline (182 mg, 1.452 mmol) in dioxane (5 mL) was heated at 80°C overnight. The mixture was cooled to RT, treated with EtOAc and satd.
• Example 73 A mixture of Example 21 (100 mg, 0.221 mmol) in pyridine (3 mL) was treated drop-wise with methylchloroformate (23 mg, 0.243 mmol) and stirred at RT for 4 h. Additional methylchloroformate (50 ⁇ ) was added and the mixture stirred overnight. The mixture was treated with additional methylchloroformate (100 ⁇ ) and stirred for another 2 days. The mixture was concentrated to dryness, treated with EtOAc and water and the resulting solid collected via filtration. The material was purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA); the organics were removed under reduced pressure and the aqueous mixture was neutralized with satd.
• Example 74 A mixture of Example 21 (90 mg, 0.199 mmol) and pyridine (79 mg, 0.996 mmol) in THF (4 mL) was treated drop-wise with methoxy acetyl chloride (27 mg, 0.249 mmol) and stirred at RT for 22 h. Additional methoxy acetyl chloride (30 ⁇ , 0.328 mmol) was added, the mixture heated at 40°C for 6 h, then cooled to RT and stirred overnight.
• Example 75 A mixture of Example A18 (752 mg, 9.0 mmol), Cs 2 C0 3 (2.0 g, 6.0 mmol) and Xantphos (173 mg, 0.3 mmol) in dioxane (10 mL) was sparged with N 2 , treated with Pd 2 (dba) 3 (165 mg, 0.18 mmol), sparged again with N 2 and heated at 100°C overnight. The mixture was cooled to RT, poured into water and extracted with EtOAc (3x).
• Example 76 A solution of Example C5 (3 g, 10.9 mmol) in DMF (50 mL) was treated with ZnCN 2 (1.7 g, 16.4 mmol) and Pd(PPh 3 ) 4 (1.26 g, 1.09 mmol), sparged with N 2 and heated at 100°C for 12 h. The mixture was cooled to RT, treated with water and extracted with EtOAc (3x).
• Example 77 A mixture of Example A52 (153 mg, 0.304 mmol), t-butyl X-phos (6.45 mg, 0.015 mmol), Cs 2 C0 3 (198 mg, 0.608 mmol), Pd 2 (dba) 3 (28 mg, 0.030 mmol) and methylamine (2. ON in THF, 2.0 mL, 4.0 mmol) in dioxane (3 mL) was sparged with Ar and heated at 80°C for 4.5 h. The mixture was cooled to RT, treated with EtOAc and DCM and the solids removed via filtration through diatomaceous earth.
• Example 78 A mixture of Example A56 (88 mg, 0.188 mmol), Cs 2 C0 3 (122 mg, 0.375 mmol) and acetamide (55.4 mg, 0.938 mmol) in dioxane (2 mL) was sparged with Ar for 15 minutes, treated with Pd 2 (dba) 3 (8.59 mg, 9.38 ⁇ ) and Xantphos (10.86 mg, 0.019 mmol), sparged again with Ar and heated to 100°C for 2.5 h. The mixture was cooled to RT, treated with 10% MeOH/DCM and the solids removed via filtration through diatomaceous earth. The filtrate was concentrated to dryness and purified via silica gel chromatography (EtO Ac/Hex).
• Example 79 A mixture of Example Dl (155 mg, 0.493 mmol), DIEA (146 mg, 1.126 mmol), 1-methylpyrrolidine (24 mg, 0.281 mmol) and Example A47 (155 mg, 0.281 mmol) in dioxane (4 mL) was heated at 80°C for 20 h. The mixture was cooled to RT, treated with EtOAc, washed with satd. NaHC0 3 , then brine, dried over Na 2 S0 4 , concentrated to dryness and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA). The organics were removed under reduced pressure and the aqueous residue treated with satd.
• Example 80 A mixture of Example A54 (0.211 g, 0.468 mmol), Bippyphos (0.024 g, 0.047 mmol), acetamide (0.332 g, 5.62 mmol) and K 3 P0 4 (0.397 g, 1.872 mmol) in dioxane (5 mL) was sparged with Ar for 15 min, treated with Pd 2 (dba) 3 (0.021 g, 0.023 mmol) and heated at 80°C overnight. The mixture was cooled to RT, diluted with EtOAc and the solids were removed via filtration.
• the filtrate was concentrated to dryness, dissolved in EtOAc/THF, washed with brine (2x), dried over MgS0 4 and concentrated to dryness. The material was treated with acetone, the solid collected via filtration and dried. The filtrate was concentrated to dryness, purified via silica gel chromatography (MeOH/DCM) and combined with the isolated solid.
• Example 81 A suspension of Example A50 (0.202 g, 0.377 mmol) and 3- hydroxyazetidine hydrochloride (0.045 g, 0.415 mmol) in THF (4 mL) was treated with 1- methylpyrrolidine (0.050 ml, 0.471 mmol) and heated at 55°C overnight. Additional 3- hydroxyazetidine hydrochloride (0.150 g) and 1-methylpyrrolidine (0.30 mL) were added and the mixture was heated at 55°C for another 24 h. The mixture was cooled to RT, diluted with water and the remaining solid collected via filtration, rinsed with THF and dried.
• the solid was purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA); the organics were removed under reduced pressure, the aqueous residue neutralized with satd. NaHC0 3 , then azeotroped with IPA to dryness. The residue was suspended in water, the solid collected via filtration and dried to afford N-(3-(2-chloro-4-fluoro-5-(3-phenylureido)phenyl)-l-ethyl- 2-oxo-l,2-dihydro-l,6-naphthyridin-7-yl)-3-hydroxyazetidine-l-carboxamide (26 mg, 13% yield).
• Example 82 A mixture of Example Dl (250 mg, 0.794 mmol), DIEA (252 mg, 1.949 mmol) and 1-methylpyrrolidine (41 mg, 0.487 mmol) in dioxane (4 mL) was treated with Example A48: (200 mg, 0.487 mmol), heated at 80°C for 4 h, then cooled to RT for 3 days. The mixture was diluted with EtOAc, washed with 50%> satd. NaHC0 3 , then brine, dried over Na 2 S0 4 , concentrated to dryness and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1 % TFA).
• Example 83 A mixture of Example Dl (250 mg, 0.794 mmol), DIEA (218 mg, 1.683 mmol) and 1-methylpyrrolidine (36 mg, 0.421 mmol) in dioxane (4 mL) was treated with Example A49 (200 mg, 0.421 mmol), heated at 80°C for 4 h, then cooled to RT for 3 days. The mixture was treated with EtOAc and DCM, washed with 50% satd. NaHC0 3 , then brine, dried over Na 2 S0 4 , concentrated to dryness and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA).
• Example 84 A solution of Example A50 (0.098 g, 0.183 mmol) in THF (3 niL) was treated with (3R)-(+)-3-(dimethylamino)pyrrolidine (0.047 g, 0.549 mmol) and 1- methylpyrrolidine (2.088 mg, 0.018 mmol) and heated at 55°C for 16 h.
• Example 85 A solution of Example A3 (500 mg, 1.420 mmol) and pyridine (449 mg, 5.68 mmol) in THF (20 mL) was treated with phenyl isocyanate (186 mg, 1.562 mmol) and stirred at RT for 20 h. The mixture was accidentally treated with a few drops of SOCl 2 ; EtOAc, water and satd. NaHC0 3 were added and the mixture stirred at RT for 2 h. The resulting solid was collected via filtration and dried. The layers of the filtrate were separated, the organic layer washed with brine, dried over Na 2 S0 4 and concentrated to dryness.
• the mixture was cooled to RT, treated with EtOAc, water and DMF, and the solids removed via filtration through diatomaceous earth.
• the layers of the filtrate were separated, the organic layer washed with brine, dried over Na 2 S0 4 , concentrated to dryness and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA).
• the organics were removed under reduced pressure and the aqueous residue treated with satd. NaHC0 3 and extracted with EtOAc (2x).
• Example 86 A mixture of Example A55 (320 mg, 0.659 mmol), Pd 2 (dba) 3 (30 mg, 0.033 mmol), Bippyphos (33 mg, 0.066 mmol), K 3 P0 4 (560 mg, 2.64 mmol) and acetamide (389 mg, 6.59 mmol) in dioxane (8 mL) was sparged with Ar and heated to 90°C for 22 h. The mixture was cooled to RT, diluted with DMF, stirred for 1 h and the solids were removed via filtration through diatomaceous earth. The filtrate was concentrated to dryness and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA).
• Example 87 A mixture of Example A51 (0.138 g, 0.320 mmol) and Example D2 (0.100 g, 0.448 mmol) in dioxane (4 mL) was treated with 1-methylpyrrolidine (6.73 ⁇ , 0.064 mmol) and heated to 80°C overnight.
• Example 88 A solution of 3-fluoro-5-nitrotoluene (1.0 g, 6.45 mmol) in trifluorotoluene (15 ml) was treated with NBS (1.721 g, 9.67 mmol) and AIBN (0.212 g, 1.289 mmol) and heated at 105°C overnight. The mixture was cooled to RT, the solids removed via filtration and the filtrate concentrated to dryness to afford l-(bromomethyl)-3- fluoro-5 -nitrobenzene (95 mg, 63% yield).
• Example 89 A mixture of Example D2 (0.060 g, 0.269 mmol) and Example A48 (0.085 g, 0.207 mmol) in dioxane (2 mL) was treated with 1-methylpyrrolidine (2 drops) and heated to 80°C overnight. The mixture was concentrated to dryness, treated with EtOAc and the resulting solid collected via filtration and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA). The organics were removed under reduced pressure, the aqueous residue treated with satd.
• Example 90 A suspension of Example A8 (0.078 g, 0.236 mmol) in EtOAc (1.5 mL) was treated with satd. NaHC0 3 (1.5 mL) followed by isopropenyl chloroformate (0.036 mL, 0.331 mmol) and the bi-phasic mixture stirred vigorously at RT overnight.
• Example D2 A mixture of Example D2 (0.060 g, 0.269 mmol) and prop-l-en-2-yl (5-(l-ethyl-7- (methylamino)-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-2,4-difluorophenyl)carbamate (0.086 g, 0.208 mmol) in dioxane (2 mL) was treated with 1-methylpyrrolidine (2 drops) and heated at 80°C overnight. The mixture was concentrated to dryness, treated with EtOAc and the resulting solid collected via filtration and purified via reverse-phase chromatography (MeCN/H 2 0 with 0.1% TFA).
• Example 91 A suspension of Example A3 (0.250 g, 0.710 mmol) in THF (10 mL) was treated with 3-cyanophenyl isocyanate (0.102 g, 0.710 mmol) followed by pyridine (0.011 g, 0.142 mmol) and stirred at RT for 2 days. The mixture was concentrated to dryness and the residue treated with MeCN.
• Example 92 A suspension of Example A3 (0.200 g, 0.568 mmol) in 3- morpholinopropan-1 -amine (1 mL) was subjected to microwave irradiation at 160°C for 30 minutes. The mixture was cooled to RT, treated with water and the aqueous liquid decanted. The material was treated with MTBE and the resulting solid collected via filtration to afford 3-(5-amino-2-chloro-4-fluorophenyl)- 1 -ethyl-7-((3-morpholinopropyl)amino)- 1 ,6- naphthyridin-2(lH)-one (150 mg, 57% yield). MS (ESI) m z: 460.1 [M+H] + .
• Example 93 A solution of Example A34 (0.200 g, 0.640 mmol) in pyridine (0.5 mL) was cooled to 0°C and treated slowly with isopropenyl chloroformate (0.073 mL, 0.672 mmol).
• Example D2 A mixture of Example D2 (0.100 g, 0.448 mmol) and prop-l-en-2-yl (5-(7-amino- 1 -ethyl-2-oxo- 1 ,2-dihydro- 1 ,6-naphthyridin-3-yl)-2-fluoro-4-methylphenyl)carbamate (0.142 g, 0.358 mmol) in dioxane (3 mL) was treated with 1-methylpyrrolidine (3 drops) and heated at 80°C overnight. The mixture was treated with DMSO (2 drops) and heated at 80°C for an additional 24 h.
• Example 94 A mixture of l-fluoro-2-methyl-4-nitrobenzene (2.5 g, 16.12 mmol) NBS (5.02 g, 28.2 mmol) and AIBN (265 mg, 1.612 mmol) in trifluorotoluene (45 mL) was heated to reflux overnight. The mixture was cooled to RT, filtered to remove solids and the filtrate concentrated to dryness.
• Example A47 200 mg, 0.363 mmol
• 3-((dimethylamino)methyl)-4- fluoroaniline 300 mg, 1.815 mmol
• 1-methylpyrrolidine 31 mg, 0.363 mmol
• the mixture was cooled to RT, treated EtOAc and satd.
• Example 95 A mixture of Example A47 (200 mg, 0.363 mmol) and Example D3 (95 mg, 0.454 mmol) in dioxane (5 mL) was treated with 1-methylpyrrolidine (31 mg, 0.363 mmol) and heated at 70°C overnight. The mixture was cooled to RT, treated with EtOAc and 50% satd. NaHC0 3 and stirred for 0.5 h.
• Example 96 A mixture of Example A50 (0.12 g, 0.224 mmol), (3S)-(+)-3- (dimethylamino)pyrrolidine (0.077 g, 0.672 mmol) and 1-methylpyrrolidine (9.53 mg, 0.112 mmol) in THF (3 mL) was heated at 60°C overnight.
• Example 97 A -20°C mixture of DIEA (552 mg, 4.27 mmol) and pyrrolidine (152 mg, 2.137 mmol) in THF (5 mL) was treated drop-wise with a solution of 2-(bromomethyl)- l-fluoro-4-nitrobenzene (500 mg, 2.137 mmol) in THF (5 mL), allowed to warm to RT and stirred for 6 h. The mixture was treated with EtOAc, washed with water, then brine, dried over Na 2 S0 4 and concentrated to dryness to afford l-(2-fluoro-5-nitrobenzyl)pyrrolidine (450 mg, 94% yield). MS (ESI) m/z: 225.1 [M+H] + .
• Example A47 200 mg, 0.363 mmol
• 4-fluoro-3-(pyrrolidin-l- ylmethyl)aniline 88 mg, 0.454 mmol
• dioxane 5 mL
• 1- methylpyrrolidine 31 mg, 0.363 mmol
• EtOAc 50% satd. NaHC0 3 and stirred for 0.5 h.
• Example 98 A mixture of Example A52 (0.27 g, 0.536 mmol), Cs 2 C0 3 (0.524 g, 1.609 mmol), N,N-dimethylurea (0.236 g, 2.68 mmol) and Xantphos (0.093 g, 0.161 mmol) in dioxane (10 mL) was sparged with Ar, treated with Pd 2 (dba) 3 (0.074 g, 0.080 mmol), sparged again with Ar and heated at 100°C overnight. The mixture was cooled to RT, the solid removed via filtration and washed with EtOAc.
• Example 99 A solution of Example A10 (0.16 g, 0.437 mmol) in NMP (3 mL) was treated with DBU (0.079 mL, 0.524 mmol) and 4-methoxybenzylamine (0.150 g, 1.092 mmol) and heated at 150°C overnight. Additional 4-methoxybenzylamine (0.05 mL) was added and the mixture heated at 150°C for 24 h. The mixture was cooled to RT, treated with brine and extracted with EtOAc (3x).
• Example 100 A solution of Example D2 (0.117 g, 0.524 mmol) and Example A53 (0.182 g, 0.437 mmol) in dioxane (4.5 mL) was treated with catalytic 1- methylpyrrolidine (2 drops) and the mixture heated at 80°C overnight.
• the mixture was cooled to RT, treated with EtOAc and satd. NaHC0 3 , filtered to remove insoluble material and the layers separated.
• the organic layer was washed with brine, dried over MgS0 4 and concentrated to dryness.
• the material was treated with a small amount of DCM, allowed to stand at RT, and the resulting solid collected via filtration and dried.
• the filtrate was concentrated to dryness, layered with a small amount of DCM and allowed to stand at RT overnight.
• Example 101 A mixture of Example A54 (308 mg, 0.665 mmol), Cs 2 C0 3 (650 mg, 1.996 mmol), N,N-dimethylurea (293 mg, 3.33 mmol) and Xantphos (115 mg, 0.20 mmol) in dioxane (10 mL) was sparged with Ar, treated with Pd 2 (dba) 3 (91 mg, 0.100 mmol) and heated at 100°C overnight. The mixture was cooled to RT, treated with EtOAc and DMF, the solids removed via filtration through diatomaceous earth and washed with water and EtOAc. The layers of the filtrate were separated, the organic layer washed with satd.
• Example 102 A suspension of N,N-dimethylazetidin-3 -amine dihydrochloride (0.071 g, 0.410 mmol) and N-methyl pyrrolidine (0.070 g, 0.821 mmol) in dioxane (4 mL) was heated at 55°C for 10 minutes, treated with Example A50 (0.11 g, 0.205 mmol) and heated at 55°C for 16 h.
• Example 103 A mixture of Example A55 (0.2 g, 0.412 mmol), Cs 2 C0 3 (0.403 g, 1.236 mmol), N,N-dimethylurea (0.182 g, 2.060 mmol) and Xantphos (0.072 g, 0.124 mmol) in dioxane (10 mL) was sparged with Ar, treated with Pd 2 (dba) 3 (0.057 g, 0.062 mmol), sparged again with Ar and heated at 100°C overnight. The mixture was cooled to RT, the solids removed via filtration and washed with water and EtOAc.
• Example 104 A solution of benzo[b]thiophene-3-carboxylic acid (0.129 g, 0.723 mmol) in toluene (5 mL) was treated with TEA (0.167 mL, 1.206 mmol) and DPPA (0.195 ml, 0.904 mmol), stirred at RT for 5 min, treated with Example A6 (0.20 g, 0.603 mmol) and heated at 100°C for 2 h.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)

Priority Applications (40)

Applications Claiming Priority (1)

Publications (1)

Family

ID=49712374

Family Applications (1)

Country Status (28)

Cited By (22)

Families Citing this family (5)

Citations (3)

Family Cites Families (3)

• 2012
  • 2012-06-07 DK DK17208408.9T patent/DK3366293T3/da active
  • 2012-06-07 DK DK12878321.4T patent/DK2858646T3/en active
  • 2012-06-07 AU AU2012327210A patent/AU2012327210B2/en active Active
  • 2012-06-07 PL PL17208408T patent/PL3366293T3/pl unknown
  • 2012-06-07 JP JP2015515992A patent/JP5883195B2/ja active Active
  • 2012-06-07 SG SG11201408133TA patent/SG11201408133TA/en unknown
  • 2012-06-07 CN CN201910368783.1A patent/CN110433162A/zh active Pending
  • 2012-06-07 CA CA2875970A patent/CA2875970C/en active Active
  • 2012-06-07 WO PCT/US2012/041378 patent/WO2013184119A1/en not_active Ceased
  • 2012-06-07 EP EP20161887.3A patent/EP3722296A3/en active Pending
  • 2012-06-07 EP EP12878321.4A patent/EP2858646B1/en active Active
  • 2012-06-07 CN CN201910368784.6A patent/CN110403938A/zh active Pending
  • 2012-06-07 HU HUE17208408A patent/HUE049958T2/hu unknown
  • 2012-06-07 ES ES12878321.4T patent/ES2663605T3/es active Active
  • 2012-06-07 EP EP17208408.9A patent/EP3366293B1/en active Active
  • 2012-06-07 MX MX2014015024A patent/MX372814B/es active IP Right Grant
  • 2012-06-07 RS RS20200633A patent/RS60406B1/sr unknown
  • 2012-06-07 BR BR112014030577-3A patent/BR112014030577B1/pt active IP Right Grant
  • 2012-06-07 CN CN201280075113.7A patent/CN104902895B/zh active Active
  • 2012-06-07 PH PH1/2018/502294A patent/PH12018502294B1/en unknown
  • 2012-06-07 SI SI201231785T patent/SI3366293T1/sl unknown
  • 2012-06-07 SM SM20200302T patent/SMT202000302T1/it unknown
  • 2012-06-07 ES ES17208408T patent/ES2797252T3/es active Active
  • 2012-06-07 MX MX2020005712A patent/MX392372B/es unknown
  • 2012-06-07 RU RU2014153920A patent/RU2664055C2/ru active
  • 2012-06-07 KR KR1020157000365A patent/KR101652229B1/ko active Active
  • 2012-06-07 LT LTEP17208408.9T patent/LT3366293T/lt unknown
  • 2012-06-07 PT PT172084089T patent/PT3366293T/pt unknown
  • 2012-06-07 PT PT128783214T patent/PT2858646T/pt unknown
• 2014
  • 2014-12-07 IL IL236110A patent/IL236110A/en active IP Right Grant
  • 2014-12-09 PH PH12014502757A patent/PH12014502757B1/en unknown
• 2020
  • 2020-05-29 HR HRP20200864TT patent/HRP20200864T1/hr unknown
  • 2020-06-10 CY CY20201100530T patent/CY1123377T1/el unknown
• 2022
  • 2022-04-05 LU LU00253C patent/LUC00253I2/fr unknown
  • 2022-04-07 NO NO2022010C patent/NO2022010I1/no unknown
  • 2022-04-07 FR FR22C1013C patent/FR22C1013I2/fr active Active
  • 2022-04-12 NL NL301169C patent/NL301169I2/nl unknown
  • 2022-05-03 LT LTPA2022008C patent/LTC3366293I2/lt unknown
  • 2022-05-09 HU HUS2200017C patent/HUS2200017I1/hu unknown

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events